PUBLISHED APRIL 2023
Health at 
the Heart
Environmental, Social, Governance

This Environmental, Social and Governance (ESG) Report describes Phibro Animal Health 
Corporation’s (“Phibro” | Nasdaq: PAHC) ESG efforts and related performance for the year 
ended December 31, 2022, and reflects consolidated company operations, unless otherwise 
noted. Included in this Report are disclosures containing relevant, industry-specific data and 
information aligned with the Sustainability Accounting Standards Board (SASB) framework, 
along with select disclosures aligned with the Global Reporting Initiative (GRI) framework.
Content within this Report should not be considered a substitute for Phibro’s filings with 
the U.S. Securities & Exchange Commission (SEC), including, but not limited to, the 
Company’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.
This ESG Report captures the many ways Phibro empowers our people, protects the 
environment, acts with integrity and engages with the communities in which we 
operate globally.
OUR ESG JOURNEY 
CONTINUES
2

A Letter From Our President, CEO and Chairman of the Board................................................5
Health at the Heart ............................................................................................................................7
Healthy Customer Relationships........................................................................................................... 10
Healthy Agriculture Community............................................................................................................ 15
Healthy Public............................................................................................................................................ 17
Our Commitments and Actions on Antibiotic Use............................................................................ 19
Environmental Stewardship................................................................................................................... 22
Risk Management: Climate Change...................................................................................................... 25
Key Priorities and Progress.................................................................................................................... 26
Social Responsibility and Well-Being.................................................................................................. 31
Key Priorities and Progress.................................................................................................................... 38
Fair and Transparent Governance......................................................................................................... 50
Key Priorities and Progress.................................................................................................................... 53
Next Steps On Our ESG Journey........................................................................................................... 57
Appendix..................................................................................................................................................... 59
GRI Index.................................................................................................................................................... 59
SASB Index................................................................................................................................................ 60
2.0
CONTENTS
1.0
3.0
4.0
5.0
6.0
7.0
3

1.0
4

As I reflect on more than fifty years with  Phibro 
- a company that traces its roots to a business 
my grandfather Siegfried Bendheim started 
in New York City back in 1914, I celebrate the 
continuation of his legacy and Phibro’s ability to 
innovate and evolve in our ever-changing world.
I am pleased to share our second annual ESG 
Report and the progress Phibro has made to 
generate positive change for people, animals 
and the planet.
2022 was yet another year where generation-
defining challenges were faced around the 
world. The COVID-19 pandemic entered its 
third year and it has never been more urgent, 
or more vital, for us as a company and as a 
society to live the One Health principles, which 
recognize the interconnectivity between the 
health of people, animals and the planet. It’s 
foundational to our motto: Healthy Animals. 
Healthy Food. Healthy World.®
For Phibro, Health is at the Heart of our 
longstanding relationships with customers, the 
agriculture community and the public.
This ethos extends to the planet through 
the methods and materials we use. Over 
the last few years, Phibro’s focus on making 
advancements in responsible and sustainable 
business practices has been just as important 
as the product advancements brought about 
by our scientific contributions, as demonstrated 
by improvements in our natural resource use 
intensity scores across most categories.
In 2022, we expanded our offerings in livestock 
vaccines for preventive health care and in 
renewable energy, as well as our pet care 
category product pipeline, as detailed in this 
Report. We are particularly proud that the 
emphasis we have put on diversity, equity 
and inclusion is beginning to show improved 
awareness. Diversity is an integral part of our 
culture; it drives team creativity, cohesion, 
flexibility and effectiveness.
Through business development efforts, we 
continue to explore technologies that will 
result in new solutions for our customers. Our 
portfolio is strong but we believe there are 
opportunities to make it even stronger 
and bring innovative solutions to the market 
to better satisfy customer needs. Our near-
term growth priorities are mapped against 
planned strategic investments which include 
pet care, nutritional specialty products and 
vaccine development projects, as well as a joint 
venture in China to develop a vaccine to combat 
African Swine Fever. In addition, we continue 
to allocate significant funding towards capital 
improvement projects, including the build-out of 
a new vaccine facility in Ireland, upgrades to our 
Quincy, Ill. nutritional specialty facilities and the 
expansion of vaccine manufacturing capacity at 
multiple locations throughout the world.
Looking ahead, we will continue to champion 
new approaches to further balance the 
equilibrium between people, animals and 
the planet.

A LETTER FROM OUR PRESIDENT, CEO 
AND CHAIRMAN OF THE BOARD
JACK BENDHEIM 
President, CEO 
and Chairman 
of the Board
5

2.0
6

7
2.0 
ESG REPORT
The idea of discovering “why” a company 
exists has become popular thanks, in part, 
to author and speaker Simon Sinek. Sinek 
argues that people don’t buy what you do, 
but rather why you do it.
So, what’s our why?
At Phibro, we’ve long appreciated the vital 
roles animals play in our lives. Our products, 
together with our people, support the 
sustainability of raising animals, uphold 
animal welfare, reinforce the human-animal 
bond and enable society to put One Health 
principles into practice, which recognize 
the interconnectivity between the health of 
people, animals and the planet.
OUR FAMILY TREE
As a company, our roots can be traced to 
1914 when Siegfried Bendheim launched 
Philipp Brothers, Inc. upon immigrating to 
New York City. Siegfried and his son Charles 
formed Philipp Brothers Chemicals, Inc. 
in 1946. We changed our name to Phibro 
Animal Health Corporation (Phibro) in 2003 
to reflect our focus on keeping animals 
healthy. Phibro became a public company in 
2014 with our initial public offering and listing 
on the Nasdaq stock exchange. Siegfried’s 
grandson, Jack Bendheim, who serves as 
President, CEO and Chairman of the Board, 
celebrated his 54th year with the company 
in 2022.
HOW WE DO BUSINESS 
We strive to operate a thriving company 
that we can be proud of and that supports 
a sustainable and inclusive economy. 
Fulfilling these goals rests on staying true 
to our unique value proposition: delivering 
exceptional customer service, high 
product-quality standards, fairness and 
responsibility, a commitment to integrity 
and building great teams and winning 
culture. Doing all of this well is 
the underpinning of Phibro’s long-term 
success, and our ability to continue to 
deliver for all our stakeholders – customers, 
the agriculture sector, employees, neighbors 
and shareholders.
 
2.0 HEALTH AT THE HEART
>1,800 employees at >50 sites
Approximately 780 product lines
Manufacture ≈70% of our products
Sales in more than 80 countries 
to more than 3,700 customers
7
BY THE NUMBERS

2.0
8
2.0 
ESG REPORT
OUR ESG STARTING LINE
In 2021, we conducted a materiality 
assessment to identify the ESG topics 
that were important to our customers, 
employees and stakeholders, and were 
most relevant to our business. With the 
assistance of a third party, we undertook 
the following rigorous process:
• Looked to peers in animal health and 
life sciences to understand the ESG 
frameworks most relevant to Phibro;
• Sourced materiality topics specific 
to the industry from applicable 
frameworks, starting with the 
Sustainability Accounting Standards 
Board (SASB) for an initial set of 
metrics, and Global Reporting Initiative 
(GRI), MSCI and S&P Global to develop 
a more holistic list;
• Surveyed key stakeholders including 
employees, executives, investors, 
financial institutions, sell-side analysts, 
creditors and trade associations; and 
• Calibrated the content of our 
inaugural 2021 Report to ensure 
it responded to our stakeholders’ 
needs and expectations.
 
True to our legacy as a dynamic, family-centric company 
that takes care of our employees, their families and the 
communities in which we operate, Phibro is committed to the 
health of animals and support for the people who care for 
them. Healthier animals will help create a healthier future for 
people and our planet.
ESG is embedded in our operations through our strategic 
decision-making and business processes as we continue to 
work with our customers and communities to reach common 
goals. Phibro has a proven track record of evolving with the 
changing times, and it is our sincere intent to accelerate our 
ESG journey.
Leadership at Phibro starts with our Board of Directors, CEO 
and senior management, and cascades across the company.
We are committed to investing in our ESG program, including 
gathering input from stakeholders. While developing our first 
ESG Report, we surveyed key stakeholders to understand 
their perspective on priority areas. We were pleased to see 
strong alignment between their interests and ours, thus 
forming the basis of the content of our ESG Reports.
The animal health community plays a key role in feeding the 
world. Despite continuous efforts of all in food and agriculture, 
there is more work to do. According to the United Nations, 
2.4 billion people – more than 30 percent of the world’s 
population – were moderately or severely food-insecure in 
2020. That’s why ESG is more than a scorecard to us, it’s our 
commitment – a commitment that’s integral to our company: 
Healthy Animals. Healthy Food. Healthy World.®
OUR CORPORATE 
ESG POLICY
2.0

9
2.0 
ESG REPORT
OUR PURPOSE
Optimize animal health and nutrition for better 
lives and a more sustainable world.
OUR MISSION
Provide safe and effective solutions for our 
customers’ unique challenges.
OUR BELIEFS
At Phibro Animal Health Corporation we believe in
• Keeping animals healthy 
Keeping animals healthy helps keep families 
healthy and helps feed a growing world
• Doing the right thing 
Doing the right thing for our customers builds 
meaningful relationships
• Focusing on our customers 
Focusing on our customers’ needs inspires our 
most inventive solutions
• Continuous investment in our people 
Continuous investment in our people, our 
company and our industry is essential for 
future growth
• Success built by a passion for excellence 
Success is built by a passion for excellence and 
the willingness of every team member to roll up 
their sleeves – we’re in this together
• Individuals making an impact 
Maintaining our flexibility, urgency and an 
environment where individuals make an impact 
is essential no matter how large we grow
OUR MISSION AND BELIEFS
In 2021, we formed our global ESG 
Council, chaired by our Chief Financial 
Officer, Damian Finio, and sponsored by 
Carol Wrenn, an independent director on 
our Board. This cross-functional Phibro 
team works diligently to advance and 
institutionalize our ESG initiatives. We’re 
serious about this process because the 
principles of ESG align with how we’ve 
done business since the very beginning. 
We care about our employees, our 
customers, our impact on communities 
and the natural resources entrusted to 
our care. We understand that providing 
animals with quality nutrition and treating 
them with respect and compassion leads 
to healthy animals. And healthy animals 
drive a more abundant supply of quality 
protein for consumers around the world.

10
2.0 
ESG REPORT
Phibro delivers a comprehensive portfolio 
of solutions for animal and plant health 
and the ethanol industry. Our research and 
development teams continually work on new 
technologies, developing and manufacturing 
safe, innovative and effective products and 
delivery systems to ensure the success of our 
customers globally.
FOR LIVESTOCK AND 
AQUACULTURE
Phibro provides a broad range of proven 
products for poultry, swine, beef and dairy 
cattle and aquaculture. We offer high-quality 
products, backed by experts dedicated to 
serving farmers, ranchers, nutritionists and 
veterinarians.
MEDICATED PRODUCTS: Our products 
prevent and treat disease to maintain the 
health and welfare of animals. Without them, 
animals can suffer from enteric diseases, 
intestinal parasites or respiratory disease.
Phibro and other members of the animal 
health industry including farmers and 
veterinarians, in conjunction with government 
regulators in many global markets, have long 
made it a priority to ensure the responsible 
use of antibiotics in animals. See pages 19-20 
for a progress update.
VACCINES: Our vaccines provide effective 
prevention against disease, prevent animal 
suffering and enable farmers to meet the 
highest standards of animal care and quality 
production. With a portfolio of vaccines for 
poultry, swine, beef and dairy cattle and 
aquaculture, we combine the right products 
with technical support and continual 
innovation.
We market a broad portfolio of fully licensed 
vaccines for poultry to key markets and 
customers around the globe. We offer 
more than 25 poultry vaccines to protect 
against deadly diseases, including Infectious 
Bronchitis, Infectious Bursal Disease, 
Newcastle Disease and infections of zoonotic 
pathogens including Salmonella, E. coli and 
Campylobacter.
 
ENDURANCE. Established in 1946 as a chemical 
company, transforming into a leader in the 
Animal Health industry driven by acquisitions and 
organic growth.
ANTICIPATION. Had the foresight to invest in 
nutritional specialty, mineral nutrition and vaccine 
products, enabling the company to grow the 
Animal Health business beyond Medicated Feed 
Additives.
OPPORTUNISTIC. Seizing opportunities to 
acquire accretive businesses: Prince Agri Products 
in 1980, Pfizer’s MFA business in 2000, Abic 
Laboratories’ vaccine business in 2009, Osprey 
Biotechnics’ micro-organism business in 2019, 
and entering the high-growth area of companion 
animals in 2019 with the launch of Rejensa®.
BREADTH. Approximately 780 product lines sold 
in more than 80 countries spanning three business 
segments: Animal Health, Mineral Nutrition and 
Performance Products.
WISDOM. Led by a seasoned CEO with more than 
50 years at the company, flanked by other corporate 
and regional senior leaders each with more than 30 
years of relevant experience at large multinational 
companies such as Schering-Plough, Elanco, Cargill, 
Novartis, Pfizer, AstraZeneca and Merck.
ALIGNMENT. A closely held public company with 
a CEO who is also the Chairman of the Board of 
Directors and a controlling shareholder, clearly 
driven by incentives aligned directly with the 
remainder of our shareholders.
10
FROM AN INVESTOR’S 
PERSPECTIVE: OUR CORE 
STRENGTHS
2.0 HEALTHY CUSTOMER 
RELATIONSHIPS

2.0
11
2.0 
ESG REPORT
Phibro developed and launched pHi-Tech® 
for poultry, a revolutionary vaccination 
system that helps ensure accurate vaccine 
administration. Our system has been 
implemented by leading poultry farms in 
dozens of countries worldwide and has been 
used to perform hundreds of millions of 
injections to enhance flock immunity.
We are currently developing pHi-Tech 
for aqua, a safe and accurate portable 
vaccination system for fish; pHi-Tech DOV, 
a cost-efficient, compact solution for 
day-old chick vaccination; and comprehensive 
software solutions to facilitate monitoring and 
data-driven decision-making on farms.
NUTRITIONAL SPECIALTIES: We set 
ourselves apart as a leading provider of 
nutritional specialty products based on 
extensive research and proven results. Our 
innovative, science-based solutions help 
achieve optimal animal health by supporting 
immune function and promoting gut health.
We offer proprietary nutritional specialty 
products developed in cooperation with 
private research companies and leading 
university partners. We go the extra mile, 
conducting field trials to confirm our 
products effectively help achieve the 
animal health and sustainability goals 
of our livestock customers.
MINERAL NUTRITION: We develop and 
manufacture custom trace mineral pre-mix 
blends that help fortify and maintain an 
optimal balance of minerals in the diet. Our 
diverse mineral portfolio includes a wide array 
of trace and macro mineral products including 
elements comprised of various forms of 
manganese, copper, zinc, cobalt, iodine, iron, 
selenium, magnesium, sulfur, potassium, 
phosphorus, calcium, sodium and chlorine. 
Our offering includes the GemStone® line of 
organic trace minerals, selenium yeast and 
chromium tripicolinate.
Many Phibro products are customized for 
individual customers to help deliver optimal 
mineral nutritional balance in animal diets. 
Good nutrition is as important for animals as 
it is for people.
 
Led by trained Phibro consultants, Our Dairy 
Values™ is an interactive exercise to help dairy 
owners define their unique purpose and values 
and put a plan in place to bring them to life.
The companion program, Vital Insight™, helps 
farmers make their operations more appealing 
places to work. Phibro works in partnership 
with Purdue University’s Center for Food and 
Agricultural Business to survey dairy employees 
regarding attributes such as engagement, 
accountability and clarity of purpose. The 
findings help dairy leaders identify what is 
working and what can be improved on their 
farms. Engaging employees and obtaining their 
feedback communicates they are valued and 
integral to the farm’s success. 
HELPING FARM 
BUSINESSES SUCCEED
(SASB FB-FR-430a.3)

2.0
12
ESG REPORT
FOR COMPANION ANIMALS
We continue to build our companion animal 
business and pipeline to improve the health 
and well-being of pets and, in turn, their 
owners. Our Rejensa® joint supplement for 
dogs continues to gain customer acceptance. 
Our companion animal development pipeline 
includes an early-stage atopic dermatitis 
compound, a novel Lyme vaccine delivery 
system product and two early-stage oral 
care compounds. We also entered into 
an agreement with Rejuvenate Bio, Inc. 
to collaborate on the development and 
commercialization of a gene therapy for mitral 
valve disease in dogs.
FOR PLANTS
Global population growth combined with 
limited land and water resources makes it 
more important than ever to maximize crop 
yields. Phibro’s Plant Solutions offers products 
used primarily in the production of grains, 
forages, fruits and vegetables, and include 
microbials and macro and trace elements. 
Microbials are used in seed treatment or soil 
application to help protect plants against 
harmful organisms and pests. Macro and trace 
element products provide a supplemental 
source of nutrients required for optimal plant 
health and production.
FOR FUEL, DISTILLERS GRAIN 
AND DISTILLERS CORN OIL
Phibro Ethanol provides tools that work 
behind-the-scenes to help create cleaner 
fuel, cleaner air and a cleaner process. 
Phibro products and services empower 
our customers to achieve efficiency in their 
fermentation facilities. This yields more low-
carbon, renewable energy from less biomass 
while also producing products for food 
and animal feed. Our solutions help biofuel 
producers worldwide provide a low-carbon 
energy solution – a solution that is positioned 
to play a significant role in the fight against 
climate change.
FOR INDUSTRY
Through our legacy chemical business, 
Performance Products, we manufacture 
and market several specialty ingredients for 
industry. Performance Products includes 
PhibroChem (a division of Phibro Animal Health 
Corporation) and Ferro Metal & Chemical 
Corporation, which supply specialty chemicals 
to the U.S. and European markets for use in 
coatings, personal care, metal finishings and a 
range of industrial applications.
Phibro-Tech, Inc. is a recycler that 
manufactures copper- and iron-based 
products and recycles permitted waste 
primarily from the electronics industry.
 
TECH & TRAINING FOR 
BRAZIL’S EGG INDUSTRY 
Across Brazil’s major egg production centers, 
Phibro offers free trainings on hen immunization 
and best practices in hen health and husbandry. 
Auditing and certification are available to 
companies so they can use the upgraded 
methods to differentiate themselves in the 
marketplace.
In 2022, 80 individuals participated in five 
trainings of up to three days each. We will 
continue to increase the scope and reach of this 
program in alignment with producer needs.
12
(SASB FB-FR-430a.3)

3.0 
13
ESG REPORT
Phibro continues to expand our livestock 
vaccine offerings for preventive health care. 
Highlights include:
JOINING FORCES
African Swine Fever (ASF) is a virulent disease 
that is highly lethal in swine. ASF’s decimation 
of China’s swine population in the late 2010s 
was not just a crisis for pigs, it was a food 
security crisis for people in many affected 
countries. Phibro, through a joint venture, is 
diligently working to commercialize a safe, 
effective, economical vaccine against ASF, 
through a novel epitope-based approach, rather 
than following the more conventional path of 
an attenuated live vaccine. The epitope-based 
vaccine formula presents zero risk of spreading 
the disease.
ACCELERATED APPROVAL 
Infectious bronchitis virus (IBV) is a significant 
respiratory pathogen affecting poultry that 
causes animal mortality and morbidity and 
costs millions of dollars in food production 
losses worldwide each year. While the poultry 
industry extensively vaccinates against IBV, 
the emergence of new serotypes and variants 
is a constant threat. Brazil – the world’s 
largest poultry exporter – experienced a 
significant outbreak in 2022, and Phibro’s 
team recognized that a vaccine in our pipeline, 
TAbic® IBVAR206, could serve as a solution. 
Phibro Brazil worked with the local industry 
organization, Brazilian Association of Animal 
Protein, and Brazil’s Ministry of Agriculture, 
Livestock and Food Supply on an intensive, 
fast-track regulatory review process. Upon 
deployment of the vaccine in early 2023, 
expected results include significant reductions 
in bird suffering and mortality, reduced rates 
of bird condemnation at the processing plant 
level and economic benefits to industry and 
the food system. Environmental benefits will 
include: saving the resources that would 
have been required to feed affected birds, 
preventing the food waste associated with 
condemnations in the processing facility and 
preventing the disposal of affected carcasses.
CAPACITY, KEEPING UP
More broadly, we continue to invest in our 
vaccine production facility in Sligo, Ireland to 
equip it to manufacture poultry vaccines. Our 
first commercial sale of product was realized 
in February 2022, and we will continue 
to invest in expanding our production 
capabilities. We also built a vaccine 
production facility in Guarulhos, Brazil, 
to manufacture and market autogenous 
vaccines against animal diseases for swine, 
poultry and aquaculture.
JOB ONE: VACCINATION INNOVATION
13
ESG REPORT
2.0

3.0 
14
ESG REPORT
JOB ONE: VACCINATION INNOVATION (CONTINUED)
14
ESG REPORT
FOCUS ON DELIVERY
Our culture of innovation led to the development 
of a new, cutting-edge delivery platform for 
vaccines. TAbic® patented tablet vaccine 
technology was developed for the formulation 
and delivery of vaccine antigens in effervescent 
tablets, replacing the traditional glass vials. The 
tablets allow for easier handling, transport and 
storage, enabling the safe delivery of much 
needed vaccines to remote locations with less 
cold-chain capabilities around the world, while 
producing less waste related to disposal of 
glass vials, as the foil used in our blister packs is 
100% recyclable.
ONE FARM AT A TIME
We expanded our vaccine capabilities in the 
U.S. when we acquired MVP Laboratories in 
2016, where we develop, manufacture and 
distribute autogenous vaccines* that protect 
against bacterial and viral diseases. These 
custom-made vaccines contain antigens specific 
to an individual farm, providing comprehensive 
health management solutions to help protect 
animal health on a farm-by-farm basis. Our 
bacterins incorporate EASE™ (Enhanced 
Antigen Surface Expression) technology for a 
purer, more defined autogenous vaccine product 
resulting in a more focused immune 
response from the host animal. In addition, 
our autogenous vaccines all incorporate MVP 
adjuvants®, a worldwide leader in formulations 
to optimize safety and immune response in the 
treated animal. 
*Potency and efficacy of autogenous biologics have not 
been established.
2.0

2.0
15
ESG REPORT
Global society faces a multitude of complex 
and overlapping challenges that threaten the 
environment, along with individual security 
and prosperity. Meaningful solutions require 
partnership. Phibro leaders and professionals 
engage in collective action at all levels of like-
minded organizations, including:
HealthforAnimals (HFA):
Based in Brussels, Belgium, this organization 
represents animal health companies and 
industry associations globally. Supporters 
and participants include manufacturers of 
veterinary pharmaceuticals, vaccines and 
other animal health products. The role of 
HFA is to foster a greater understanding of 
the interconnected nature of human health, 
animal health and the environment, and to 
engage in regulatory affairs. Phibro serves in 
various leadership roles, directly contributing 
to resources leveraged by the broader 
animal health sector and amplifying the 
organization’s important messages.
See pages 19-20 for more on Phibro’s 
leadership position in HFA’s platforms on 
responsible antibiotic use.
INSTITUTE OF FEED 
EDUCATION & RESEARCH 
(IFEEDER): 
IFEEDER advances understanding 
and trust in a sustainable animal feed and pet 
food supply chain through timely research 
and education. Founded in 2009 by the 
American Feed Industry Association (AFIA), 
the non-profit seeks to earn public trust 
through transparency and collaboration. 
Current and future initiatives include 
supporting the Clarity and Leadership for 
Environmental Awareness and Research 
(CLEAR) Center at University of California 
Davis. Led by Dr. Frank Mitloehner, CLEAR 
uses research and communication to help 
animal agriculture operate more efficiently 
in order to meet demands of a growing 
population and lessen its impact on the 
environment and climate. Research includes 
the important work of quantifying and 
mitigating greenhouse gas (GHG) emissions 
from livestock.
Over the course of 2022, IFEEDER developed 
the Animal Food Industry Sustainability 
Road Map and Toolkit with the goal of giving 
members a solid starting point for reducing 
their environmental impacts and helping 
consumers feel good about where their 
food comes from. The roadmap is designed 
to provide life cycle data up and down the 
production chain and explore the scope of 
sustainability guidance and resources needed 
by the animal food industry for continuous 
improvement.
IFEEDER supports the North American Meat 
Institute and AFIA’s involvement in several 
organizations with shared values, such as 
U.S. Roundtable for Sustainable Beef and U.S. 
Farmers and Ranchers in Action.
Phibro is a member of AFIA and a 
contributor to IFEEDER, providing ongoing 
leadership, engagement and support. 
Phibro representatives have served on 
both organizations’ boards in the past and 
continue to serve on IFEEDER’s board of 
trustees today.
2.0 HEALTHY AGRICULTURE 
COMMUNITY

2.0
16
ESG REPORT
WOMEN IN FOOD AND 
AGRICULTURE (WFA): 
Recognizing more can be done to help 
women contribute to a fair, responsible and 
sustainable food and agriculture system 
that feeds an exponentially larger global 
population, Phibro joined WFA in 2022. WFA 
is a unique platform that enables people to 
meet, discuss and share experiences and 
ambitions. Progressive and disruptive 	
industry leaders support its mission 	
though various projects. 
Phibro rallied our employee base around 
the WFA Digital Festival, an opportunity to 
upgrade personal skills, leadership abilities, 
technical knowledge and sustainability 
practices. This also connected our team 
with an engaged community across the 
entire agribusiness supply chain where 
the achievements of those who are the 
backbone of the world’s food systems 
were celebrated. This was the first year of 
Phibro’s involvement, and we were pleased 
to have more than 130 professionals, 
including all levels and disciplines from 
human resources to marketing. The virtual 
format enabled participation from the U.S., 
Canada, Argentina, Brazil, Columbia, Costa 
Rica, Mexico, Panama, Israel, China, Taiwan, 
Ireland, Poland, Egypt, Turkey and Australia.
WOMEN OF LOT 
FEEDING (WOLF): 
In Australia, Phibro partners with WOLF to 
mobilize gender equality in the workplace 
and society. WOLF aspires to help women 
overcome challenges in their careers in the 
lot feeding industry, especially while they 
are starting a family. WOLF also facilitates 
mentoring programs and creates awareness 
of mental health in the workplace.
PHIBRO IS ALSO ACTIVE WITH:
• Animal Agriculture Alliance (AAA): 
AAA brings together farmers, ranchers, 
veterinarians, animal feed companies, 
animal health companies, processors, allied 
associations and others involved in the 
agri-food value chain.
• Dairy Sustainability Alliance®: This multi-
stakeholder group includes companies and 
organizations across the dairy community 
dedicated to contributing to dairy’s social 
responsibility journey. In 2022, Phibro, the 
Innovation Center for U.S. Dairy and Dairy 
Management Inc. hosted an in-person 
symposium, “Health and Sustainability: A 
Focus on Dairy Animal Nutrition, Feeding 
and Management,” focused on cow health 
and feeding practices that contribute to U.S. 
dairy farm sustainability.
• Distillers Grains Technology Council 
(DGTC): DGTC is a non-profit organization 
that provides educational and technical 
services to improve the quality, value 
and utilization of distillers grains in 
the fuel ethanol, beverage alcohol and
 livestock industries.
• International Poultry Council (IPC): IPC 
is the voice of the global poultry meat 
industry, comprised of national sector 
associations, poultry businesses and other 
key industry stakeholders like Phibro.
• U.S. Grains Council (USGC): USGC 
develops export markets for U.S. barley, 
corn, sorghum and related products 
including distiller’s grain and ethanol. 
The Council believes exports are 
vital to global economic development and 
to U.S. agriculture’s profitability.
 
16

2.0
17
ESG REPORT
Phibro is a leader in the animal health 
sector, a sector that plays a significant role 
in advancing the United Nations Sustainable 
Development Goals (SDGs). Launched in 
2015, the 17 SDGs are a call-for-action to 
make measurable progress to end poverty, 
ensure prosperity for all people and protect 
the planet by 2030.
IMPROVED ANIMAL HEALTH CAN HELP US:
• Meet rising global demand for safe, 
nutritious and affordable animal protein
• Reduce emissions
• Mitigate the threat of zoonoses and 
future pandemics
• Keep pace with the needs of a growing 
pet population
• Improve the livelihoods of the 1.3 billion 
people who rely on livestock herding for 
food and income, and as a store of wealth, 
collateral or safety net in times of need
As a member of HFA (see page 15), Phibro 
is united with those in the animal health 
sector throughout the world in collaborating 
and supporting actions that help protect the 
health and well-being of animals and also 
support the SDGs. This includes:
• Supporting the sustainability of keeping 
animals. By delivering innovation, expertise 
and services that keep animals healthy, raising 
animals requires fewer planetary resources 
and has a lower environmental impact.
• Upholding animal welfare. Minimizing the 
burden of disease and ill health improves 
the quality of life of pets and livestock, 
allowing them to thrive and reach their 
full potential.
• Increasing access to veterinary care. 
Supporting the training and professional 
development of veterinary professionals 
around the world offers multiple benefits 
for public health, animal agriculture, 
environment and pet ownership.
• Reinforcing the human-animal bond. 
Maintaining the health and well-being 
of pets safeguards the benefits of their 
companionship, while reducing the risk of 
disease for the animal and owner.
• Strengthening “One Health.” Protecting 
animals against disease means a stronger 
defense against the health threats shared 
by people, animals and the environment.
RECENT REPORTS THAT PUT THE 
ANIMAL HEALTH SECTOR’S SOCIETAL 
CONTRIBUTIONS INTO PERSPECTIVE 
INCLUDE:
• Global Trends in Animal Antibiotic Use, 
which analyzes global data to understand 
how efforts are progressing to better 
understand and tackle antimicrobial 
resistance.
• Global Trends in the Animal Health Sector, 
which outlines how the animal health 
sector is positioned to be a leading force for 
positive change in the coming years.
2.0 HEALTHY PUBLIC

2.0
18
ESG REPORT
Phibro’s portfolio has broadened and 
evolved in alignment with the sector based 
on customer needs. As reported to our 
investors, the concentration of sales in 
MFAs and Other (a product category that 
includes: anticoccidial medicines and other 
parasiticides, antibiotics – the majority of 
which are not considered medically important 
for humans, plus antibacterial products and 
other processing aids used in the ethanol 
fermentation industry) has decreased from 
46% of sales to 39% from calendar year 
2014 to 2022. 
From 2014 to 2022, vaccine net sales 
increased from $48 to $91 million and 
nutritional specialty product net sales 
increased from $73 to $167 million, an 89% 
and 129% increase, respectively.
In concert with ongoing advances across 
our product portfolio, we are working within 
agriculture communities in developing 
economies to improve access to veterinary 
services, diagnostic laboratory networks and 
veterinary training. Animal health products 
and veterinary expertise are equally 
important to help ensure healthier animals 
produce the meat, milk and eggs needed to 
nourish the populations in these regions.
We are also making strides in countries like 
the U.S. where livestock care is sophisticated. 
Precision animal health technologies help 
provide livestock farmers access to the data 
they need to manage their animals more 
efficiently – helping to prevent disease and 
treat sick animals – and improve the quality, 
affordability and sustainability of meat, milk 
and eggs.
18

2.0
19
ESG REPORT
HFA serves as the secretariat 
for a commitment framework 
supported by organizations 
representing over 200 companies 
and 700,000 veterinarians. 
Its basis is, “Our vision is 
a world where veterinary 
antibiotics are used responsibly 
to protect and treat animals, 
and where they maintain their 
value as a therapeutic tool. An 
equally important challenge is 
maintaining and increasing food 
safety and security.”
To address these interconnected 
challenges, Phibro has committed 
to the five principles that have 
been embraced sector wide, as 
well as specific, practical actions 
to support them:
2.0 OUR COMMITMENTS AND ACTIONS ON 
ANTIBIOTIC USE
1: PROTECT ANIMAL HEALTH AND WELFARE IN A UNIFIED ONE HEALTH APPROACH
• Provide a broad range of animal health tools 
including vaccines, nutritional specialty 
products, direct fed microbials, medicated 
products and mineral nutrition
• Actively participate in veterinary and animal 
associations around the world
• Improve access to vital veterinary products 
by engaging with the Veterinary International 
Conference on Harmonization (VICH), a 
global intergovernmental body, to establish 
standardized criteria and processes for 
veterinary medicines 
• Establish the Integritas™ platform to capture 
and analyze field data to measure the health 
status of poultry flocks and better understand 
the interaction of these layers of information to 
help improve performance, animal welfare and 
food safety
• Develop vaccines for poultry to aid in the 
reduction of Salmonella to help prevent 
food-borne illness from meat and eggs 
(SASB FB-FR-260a.2)
• Maintain quality assurance of products to avoid 
pathogen introduction
2: 
• Provide education and tools that increase 
awareness and support the judicious and 
responsible use of antibiotics by customers
• Provide technical expertise to university 
students and customers learning best practices
• Participate in responsible use coalitions and 
online training for farmers and veterinarians 
USE ANTIBIOTICS JUDICIOUSLY AND RESPONSIBLY

2.0
20
ESG REPORT
4: 
INVEST IN DEVELOPMENT OF PRODUCTS 
FOR PREVENTION AND TREATMENT
• Develop new vaccines
• Provide natural products that help maintain 
immune and intestinal health in livestock, 
poultry and aquaculture
• Invest in vaccine delivery systems and 
software technologies to capture and help 
improve the quality of the vaccination process
• Research and build understanding of 
beneficial bacteria and nutritional products 
that help promote gut health and reduce the 
need for antibiotics
5: 
INCREASE KNOWLEDGE, TRANSPARENCY 
AND COMMUNICATION
• Provide access to leading experts and peers 
for an exchange of ideas  through Phibro 
Academy, a free digital learning and content 
platform
• Engage consumers on relevant animal 
and One Health topics through 
ExploreAnimalHealth.org
• Share information and tips for our customers 
to prevent and manage disease on social 
media and websites
• Present at scientific conferences and 
universities, and publish in industry and 
scientific journals

3: PROMOTE DISEASE PREVENTION AND INCREASED ACCESS TO PRODUCTS AND EXPERTISE
• Train farmers, ranchers, nutritionists and 
veterinarians on product use and best practices to 
prevent disease
• Equip the dairy community with research insights, 
best practices and strategies to consider when 
feeding and managing dairy cows through the 
“You Herd Right” podcast
• Produce a unique and effective vaccine to protect 
meat chickens from the devastating effects of 
Infectious Bronchitis variant 2
• Tailor vaccines to specific diseases on the farm 
(autogenous vaccines), giving veterinarians and 
farmers a valuable tool to help keep animals 
healthy 
• Utilize beneficial bacterial library for custom 
livestock and poultry feed applications that 
support the gut microbiome and overall animal 
health
• Improve nutritional health of livestock, poultry and 
companion animals through mineral products
(SASB FB-FR-430a.3)
2.0

3.0
21

3.0 
22
ESG REPORT
Developing solutions to environmental challenges is 
important for people, for animals and for our planet. The 
animal health sector has a unique role to play, particularly in 
mobilizing the capital necessary to develop new technologies 
and in enhancing the very infrastructure that supports 
sustainable food systems.
Phibro’s R&D and manufacturing facilities strive to uphold 
the highest standards and our raw materials 
have long been sourced in a responsible manner. 
Employee-led sustainability committees at 
our manufacturing facilities spearhead 
efforts to recycle, reduce waste and 
lower energy consumption.
As global demand for protein 
increases and Earth’s 
natural resources remain 
constrained, the need for 
efficient food production and 
renewable energy has never 
been more urgent.
 
3.0 ENVIRONMENTAL 
STEWARDSHIP
Phibro manufacturing in Israel has made significant investments into 
equipment and process design to reduce waste and reuse inputs.
The Neot Hovav facility currently recovers about 95% of the solvents 
it uses and has eliminated 65% of ammonium sulfate waste via the 
absorption of ammonia gas emissions from one process for use in 
another. In addition, the plant converts 100% of its ammonium chloride 
waste into fertilizer for agriculture.
Globally, the dominant application of ammonium chloride is as a 
nitrogen source in fertilizer. It also has nutritive value for yeasts in 
the bread-making process and in animal feeds. 
Adoption of these systems has reduced the landfilling of ammonia 
salts waste by 250 tons per year, which is an approximate 30% 
reduction.
In 2022, the Neot Hovav facility’s leadership team originated 
a breakthrough program, in conjunction with Israel’s 
Ministries of Economy and Agriculture, to repurpose 200 
tons of ammonium chloride as fertilizer for hundreds 
of acres of kale and other crops, at no cost to the 
farmers. The donation was culturally significant 
because it coincided with the Tu BiShvat holiday in 
the Jewish religion, which honors agriculture.
This project was made possible by a combination 
of empowering our employees to find sustainable solutions 
and government efforts to encourage collaborations that 
support a circular economy. Critical thinking on how to 
utilize this government program helped to divert waste from 
landfills, save costs and energy and help create new jobs 
and opportunities. (GRI 306-2)
MANUFACTURING BYPRODUCTS BENEFIT 
VEGETABLES, ENVIRONMENT
22
ESG REPORT

3.0 
23
ESG REPORT
RENEWABLE ENERGY IS 
OUR BUSINESS
Biofuels like plant-based ethanol are a low-
carbon, clean fuel that can play a vital role in 
reducing society’s dependence on fossil fuels. 
Growing the share of renewable biofuels 
in the world’s fuel supply – especially in 
those regions where the wholesale adoption 
of electronic cars is not currently feasible 
– is expected to play a significant role in 
achieving global GHG emission and other 
environmental goals.
Phibro’s core technical competencies in 
fermentation enable ethanol producers 
worldwide to yield more energy per bushel 
of corn, sugar or alternative feedstocks. 
Phibro products and services empower our 
customers to achieve higher efficiency in their 
fermentation facilities. With our help, today’s 
ethanol producers are providing low-carbon, 
renewable energy while preserving the world’s 
natural agricultural resources. By 2050, the 
U.S. biofuels community plans to achieve net-
zero lifecycle GHG emissions, on average. 
SCIENCE PAVES THE WAY 
FOR GREEN CHOICES 
Phibro Biotechnics, a division of Phibro, is 
a microbiology business that helps other 
companies meet sustainability goals naturally 
by growing various species of beneficial 
bacteria. Each species and strain specifically 
provides unique solutions that deliver 
environmental, production and/or animal 
health benefits. Microbiologists and research 
scientists work with a team of production 
experts to bring novel media formulas and 
strains of bacteria to companies in the U.S. 
and globally.
For example, Abundance®, a fertilizer 
companion microbial solution for plant health, 
provides beneficial microorganisms to work 
with the soil to help provide improved nutrient 
and mineral uptake. Each product is formulated 
with ingredients that work synergistically 
to target the needs of an individual plant to 
produce consistent growth, enhance crop 
nutrition and maximize yields.
RESPONSIBLE LIVESTOCK 
CHALLENGE: CROWDSOURCING 
NEW CONCEPTS
Phibro Brazil engaged a wide swath of the 
cattle production community in an award-
winning campaign to promote best practices for 
managing beef cattle, in accordance with the 
animal welfare recommendations of the World 
Organization for Animal Health.
Phibro Brazil, the Brazilian Beef Exporters 
Association, Athenagro (the largest livestock 
consultancy in Brazil) and Notícias do 
Front, along with nearly 95 local companies 
supporting this initiative, gathered more than 
70 project submissions from members of the 
cattle production community. Finalists were 
selected by a board of experts, and ultimately, 
a public vote determined the winner. Publicity 
of this initiative reached 6 million people and it 
won the top Rural 2021 award as “Best Market 
Action in Animal Welfare.”

2.0
24
2.0 
ESG REPORT
3.0 
Phibro has long been dedicated to reduce 
/ reuse / recycle principles across markets 
and facilities. In 2022, our Sligo, Ireland 
manufacturing facility introduced multiple 
new initiatives:
REDUCTION IN PURIFIED WATER 
CONSUMPTION
The purified water storage system in 
Sligo, Ireland utilizes a 5,000-liter tank. 
The tank is drained each week to facilitate 
the thermal sanitization of the storage 
and distribution system. Having assessed 
consumption, employees determined the 
tank could operate at a lower water level 
during production, thus saving 78,000 
liters of water each year.
ELECTRICITY SAVINGS
The production of Phivax vaccines in 
an effervescent tablet format requires 
a cleanroom where air humidity is kept 
low using dehumidification equipment. 
In alignment with our sustainable 
manufacturing ethos, we determined the 
equipment could be set to a lower power 
level during non-production periods with 
no impact on product quality. This reduces 
CO2 emissions by 22 tons per year and 
reduces electricity consumption.
WASTE MANAGEMENT
The plant achieved “Zero Waste to 
Landfill” through the introduction of: 
• Color-coded bins and labels to facilitate 
waste segregation
• Compactors that mix recycling waste in 
bulk prior to transport
• Extra waste storage capacity to reduce 
traffic to site
• Packing lists for compatible hazardous 
material to ensure drum capacity is 
maximized 
• Strict inventory control that keeps 
expired material to a minimum
PURIFYING WATER WITHOUT 
WASTE 
As California and other states update 
safe drinking water regulations, Phibro 
is well positioned to assist in a safe, 
regulatory-compliant and cost-effective 
manner. Ion exchange is an EPA-
approved, best available technology to 
purify drinking water, but it leaves behind 
hexavalent chromium, a hazardous 
waste. Phibro-Tech, Inc. collects this 
waste in a specialty tanker, converts it to 
non-hazardous trivalent chromium and 
recycles the water. The recycled water is 
then delivered back to the local sanitation 
district where it is further treated and 
used for groundwater replenishment or 
non-potable water applications, such 
as irrigation. 
RESOURCEFUL EMPLOYEES FIND NEW RESOURCE SAVINGS
(SASB FB-MP-140a.2)

3.0 
25
ESG REPORT
The employees of Phibro and our Board 
of Directors are committed to sound and 
transparent corporate governance principles 
that strengthen accountability, oversight and 
alignment with key stakeholders.
Our principles, which focus on effectively 
managing risk and preserving long-term, 
sustainable value for the benefit of our 
shareholders, our employees and the broader 
ecosystem in which we operate, are outlined 
in the Fair and Transparent Governance 
section 5.0 of this Report.
In 2022, Phibro performed our second annual 
global Strategic Risk Assessment. The list of 
risks identified in the prior year was updated, 
each risk was assigned to an owner, our 
strategy to monitor and mitigate the risk was 
defined and agreed upon and the results 
were shared with the Board of Directors with 
further actions taken where necessary. We 
also review progress and the evolution of the 
external landscape annually. This year’s focus 
was on the global macroeconomy and its 
impact on our financial performance.
In addition to the information set forth in 
this ESG Report, we acknowledge that the 
risks set forth in the “Risk Factors” section 
of our most recent Annual Report on Form 
10-K, and in our subsequent reports filed 
with the SEC, could materially affect our 
business, including those risks related to 
climate change.
For details, see our 2022 Annual Report on 
Form 10-K.
Phibro 
recognizes
climate change could have a material adverse impact on our 
operations and our customers’ businesses. Our companywide 
ESG initiative, in part, addresses this risk, as well as our 
engagement in sector-wide sustainability platforms.
3.0 RISK MANAGEMENT: 
CLIMATE CHANGE

3.0 
26
ESG REPORT
Based on Phibro’s Materiality Assessment, we 
track and report our progress against the following 
Environmental Stewardship topics: GHG Emissions, 
Energy Management, Energy Sourcing, Water 
Management and Waste & Hazardous Substance 
Management. Relevant SASB and GRI metrics, 
along with our current and prior years’ data, follow:
The figures in both tables include global, 
companywide manufacturing and R&D facilities 
and exclude administrative offices.
GHG EMISSIONS
CODE
TOPIC
DATA
SASB FB-MP-110a.1
GHG: 
Gross global Scope 1 
emissions
2022           2021           2020          
27,297      25,387        23,341    Metric Tons CO2
2022
2021
2020
Revenue in Millions
$972
$879
$798
GHG Scope 1 (MT CO2)
27,297
25,387
23,341
GHG Scope 2 (MT CO2)
15,838
14,999
14,420
Total GHG (MT CO2)
43,135
40,386
37,761
Intensity Score per $1 Million in Revenue
44
46
47
*Phibro uses an “intensity score” based on the “intensity ratio” concept defined by GRI Guidelines. 
The intensity scores shown here are intended to normalize environmental impact data by defining 
the metric in the context of Phibro’s annual revenue. The intensity score is calculated by dividing the 
absolute environmental metric (the numerator) by annual revenue (the denominator). In combination 
with Phibro’s absolute environmental impact data, the intensity scores help to contextualize the 
organization’s efficiency and track progress by improving year to year comparability.
3.0 KEY PRIORITIES 
AND PROGRESS
Notes: Revenue reflects calendar year revenues, in millions of U.S. dollars.
We are providing company-wide Scope 1, Scope 2 and 
Total GHG emissions as a factor of Phibro’s total revenue, 
for a year-on-year comparison that accounts for the 
company’s growth trajectory (the “Intensity Score”). As a 
company that manufactures the majority of the products 
we sell, Phibro management believes the Intensity Score is 
the best measure of our relative metrics and is a preferred 
metric among some in our peer group in the context of our 
GHG, energy management, water management and waste 
management. While the absolute measurements in these 
categories may go up or down year to year, we believe that 
when divided by our annual revenue, these scores will help 
make annual comparisons more meaningful, and better 
reflect the results of our efforts in these areas.
Per EPA, Scope 1 emissions are direct GHG emissions that occur from sources that are controlled or owned by an organization (e.g., 
emissions associated with fuel combustion in boilers, furnaces, vehicles). Scope 2 emissions are indirect GHG emissions associated 
with the purchase of electricity, steam, heat or cooling.
WHAT IS AN INTENSITY SCORE*?

3.0 
27
ESG REPORT
Note: Many of Phibro’s manufacturing facilities 
are located in areas with strong access to 
renewable-sourced electricity. As a result, 
more than 50% of Phibro’s third-party 
sourced electricity needs for manufacturing 
are from green or renewable sources.
ENERGY SOURCING
Sources of Purchased Electricity for 
Manufacturing Facilities*
2022
2021
2020
Renewable - Solar
0.9%
0.9%
1.1%
Renewable - Wind
6.9%
7.0%
7.1%
Renewable - Hydroelectric
55.3%
42.0%
43.0%
Nuclear
3.2%
3.0%
4.1%
Geothermal
0.1%
0.1%
0.1%
Biomass
5.3%
5.4%
6.0%
Non-Renewable
28.3%
41.6%
38.6%
* The percentages have been estimated based on locations where the source data is readily available.
ENERGY MANAGMENT
CODE
TOPIC
DATA
SASB FB-MP-130a.1
Energy Management:
1) Total energy consumed
2) Percentage grid electricity (may 
include renewable inputs into 
the grid per Energy Sourcing 
table below)
3) Percentage on-site renewable
2022           2021           2020          
904,301     885,179       857,611
2022           2021           2020          
50.0%         49.4%          50.1%
2022           2021           2020          
1.8%            0.50%           N/A

3.0 
28
ESG REPORT
ENERGY CONSUMED
2022
2021
2020
Revenue in Millions
$972
$879
$798
Energy in Gigajoules (GJ)
904,301
885,179
875,611
Intensity Score per $1 Million in Revenue
930
1,007
1,097
WATER MANAGEMENT
2022
2021
2020
Revenue in Millions
$972
$879
$798
Total Water Withdrawn (M3)
1,265,797
1,074,459
862,995
Intensity Score per $1 Million in Revenue
1,302
1,222
1,081
Total Water Discharged (M3)
456,835
435,283
531,019
Intensity Score per $1 Million in Revenue
470
495
665
For context, we are providing companywide Total Energy Consumed as a factor of Phibro’s total revenue, 
the Intensity Score. The above figures include global, companywide manufacturing and R&D facilities and 
exclude administrative offices.
For context, we are providing companywide Total Water Withdrawn in cubic meters (M3) and Total 
Water Discharged in cubic meters as a factor of Phibro’s total revenue, the Intensity Score. The above 
figures include global, companywide manufacturing and R&D facilities and exclude administrative offices.
(SASB FB-MP-140a.1)

3.0 
29
ESG REPORT
WASTE & HAZARDOUS SUBSTANCE MANAGEMENT
CODE
TOPIC
DATA
GRI 306-2
Waste:
a) Actions, including circularity measures, taken to prevent 
waste generation in the organization’s own activities 
and upstream and downstream in its value chain, and to 
manage significant impacts from waste generated.
b) If the waste generated by the organization in its own 
activities is managed by a third party, a description of 
the processes used to determine whether the third party 
manages the waste in line with contractual or legislative 
obligations. c) The processes used to collect and monitor 
waste-related data.
In accordance with Phibro’s Waste Management Policy, minimizing waste is an ongoing practice 
at all our facilities driven by cost and/or sustainability. Most of our facilities have recycling best 
practices in place for pallets, plastics, cardboard, etc. Certain facilities reuse yield from dust collectors 
into new batches. Certain facilities that have hazardous waste practice substitution of hazardous 
chemicals, as well as waste minimization. Certain facilities work on larger-scale projects. For example, 
Phibro Brazil’s Bragança Paulista location eliminated 90% of its methanol and ammonium sulfate 
waste. Other small projects are ongoing. This past year, for example, Phibro Argentina completed 
construction of a new state of the art hazardous waste storage area, and in State College PA the lab 
has replaced all hazardous florescent mercury-containing bulbs to LEDs and thus no longer needs 
universal waste disposal.
2022
2021
2020
Revenue in Millions
$972
$879
$798
Hazardous Waste (MT)
9,793
9,852
12,333
Intensity Score per $1 Million in Revenue
10.1
11.2
15.5
Non-Hazardous Waste (MT)
14,382
13,459
15,575
Intensity Score per $1 Million in Revenue
14.8
15.3
19.5
Recycling Quantities (MT)
23,805
22,924
20,562
Intensity Score per $1 Million in Revenue
24.5
26.1
25.8
For context, we are providing companywide total amounts of Hazardous Waste, Non-Hazardous Waste and 
Recycling Quantities in metric tons (MT) as a factor of Phibro’s total revenue, the Intensity Score. The below 
figures include global, companywide manufacturing and R&D facilities and exclude administrative offices.
29
(GRI 306-2)

4.0
30

4.0 
31
ESG REPORT
Phibro aspires to demonstrate excellence in 
all facets of our business. In the social realm, 
this means being supportive, transparent 
and accountable to our employees, partners 
and customers and, importantly, to the 
broader communities we touch. We deliver 
safe, effective and affordable products in 
more than 80 countries around the world, 
and we invest in the communities we work 
with daily. Our commitment to excellence is 
evident through our achievements in product 
safety, employee health and wellness, 
affordability and access, animal welfare and 
community relations.
EARNING EMPLOYER-OF-
CHOICE STATUS BASED ON 
ENGAGEMENT SURVEY
Internally, Phibro strives to nurture a strong 
culture that empowers team members 
and provides opportunities for growth and 
development. The Denison Organization 
Culture survey was administered to all 
employees globally in 2017 and 2021, with 
at least a 75% response rate each time. 
Phibro employee engagement and 
commitment scores remained consistent 
in 2017 and 2021 with 82% responding 
favorably for engagement and 76% for 
commitment. A pulse survey related to 
specific indices was conducted in 2022.
We are intently focused on maintaining 
or improving these results across the 
organization.
Achievement of business objectives and the 
fulfillment of individual career aspirations are 
reinforced by our:
• Competitive compensation and 
benefit programs
• Comprehensive training and 
development programs
• Health and safety programs that promote 
and safeguard employees’ well-being
• Work environments that are conducive to 
the successful application of skills 
and knowledge
In addition to traditional professional 
development, we offer a robust, cloud-based 
online training curriculum from Percipio™, 
one of the leading providers of development 
material for learning-focused organizations. 
 
4.0 SOCIAL RESPONSIBILITY 
AND WELL-BEING
In recent years, Phibro’s South American 
Region (SAR) has faced significant challenges 
in its human resources department. Not only 
were HR leaders responsible for implementing 
a global, cloud-based Human Resources 
Information System that collects and stores all 
employee data, but they were integrating an 
acquired company, internalizing the payroll and 
implementing several new controls. And, much 
of this was happening against the backdrop of a 
global pandemic.
Of SAR’s 51 new hires in the three years prior, 
12 nationalities were represented and nearly 
half were female. Each of the projects required 
different competencies and abilities to develop 
solutions that worked to the company’s and 
to stakeholders’ benefit. According to local 
leadership, the various backgrounds, strengths 
and preferences of the employee base were key 
to surmounting these seemingly insurmountable 
professional challenges.
DIVERSITY DRIVES VIBRANT 
CULTURE AND INNOVATION 
AT PHIBRO

4.0 
32
ESG REPORT
We encourage employees to take advantage 
of the many development opportunities 
that Phibro offers. In 2022, our employees 
accumulated 20,790 of training hours via this 
platform, which correlates to approximately 
11 hours per employee on average.
In the Asia Pacific region, we rolled out a series 
of Meet, Share and Learn sessions for people 
managers to develop core capabilities for 
personal and organizational development.
By offering above-and-beyond health 
benefits that meet or exceed market-driven 
expectations, we cultivate a culture of wellness 
and disease prevention among our employees. 
For example, in Brazil we carry out annual 
Pink October and Blue November campaigns 
to generate employee awareness of the 
importance of prevention and early detection 
of breast and prostate cancer. The campaigns 
involve a series of engaging activities including 
lectures, walk-a-thons, informative materials 
and thematic gifts.  
STRENGTH THROUGH 
DIVERSITY, EQUITY AND 
INCLUSION (DEI)
We create a positive and supportive work 
environment for our employees. Our approach 
enables opportunity for inclusion and 
encourages diverse perspectives and thinking 
to maximize the achievement of innovative 
and successful outcomes. We aim to protect 
employees from being discriminated against 
on the basis of gender, sexual orientation, age, 
marital status, race, religion, political beliefs, 
ethnic background, country of origin, language 
or non-job-related disabilities, and we follow 
these same principles when recruiting new 
talent to our organization.
We implemented a new, mandatory DEI 
training program in 2022 to foster awareness 
and acceptance across our administration, 
R&D and manufacturing facilities. In many of 
our locations, we have invested even further 
by bringing in highly regarded guest experts to 
deliver interactive educational sessions on DEI 
topics and engage in dialogue with employees.
 
Phibro invests in multiple outreach programs 
targeting distinct audiences to help bridge the 
gap between scientists, producers and the 
consuming public:
Phibro Academy, a digital learning and content 
platform, allows customers and partners to continue 
to learn and exchange ideas with leading experts 
and peers via live webinars and recorded e-learning 
modules. The content spans a range of practical 
animal health, nutrition and management topics 
across species.
The “You Herd Right” podcast 
updates the dairy community 
on research and best practices 
and strategies to consider when 
feeding and managing dairy cows. 
The audio format is invaluable 
to farmers who can tune in right 
from the tractor or the barn.
Dr. Leah Dorman is a respected 
veterinarian, farmer and mother of three children. 
She takes seriously her oath to protect animal 
health and promote human health, which she does 
every day as Phibro’s Director of Communication 
and Consumer Engagement. Dr. Dorman posts 
responses to questions from the public and original 
commentary at ExploreAnimalHealth.org. Recent 
topics include food waste, highly pathogenic avian 
influenza and responsible use of antibiotics. 
(SASB FB-FR-430a.3)
PHIBRO SPREADS AWARENESS 
AND SHARPENS KNOWLEDGE

4.0 
33
ESG REPORT
Phibro employees are our greatest strength 
and most valuable asset. When we equip 
team members to apply their skills, talent 
and passions to contribute and make a 
positive impact, everyone succeeds. When 
we thrive as individuals and teams, the 
company thrives. We look to promote 
from within when possible, safeguard the 
confidentiality of employee records and keep 
employees informed of issues affecting them.
INVESTING IN WORKPLACE 
SAFETY MAKES SENSE
We are committed to manufacturing safe 
products and achieving a safe workplace. Our 
Environmental Health and Safety (EHS) Global 
Director along with regional and site-based 
EHS professionals manage comprehensive 
EHS policies, programs and processes at each 
manufacturing site. External EHS audits are 
performed as needed.
The safety of Phibro employees who 
drive a company vehicle – primarily sales 
representatives – has long been a priority. 
Courses on safe driving are provided by the 
company, on company time and at company 
expense, at a minimum of every three years. 
There were 127 drivers in the U.S. who 
participated in our Fleet Safety Program in 
our fiscal year ended June 30, 2022, and we 
continue to expand the program globally. The 
upshot: Phibro achieved our annual goal to 
reduce fleet safety incident claims and costs.
Each region implements customized, culturally 
relevant fleet safety campaigns as well; for 
example, the 2022 Safety Week campaign in 
Brazil engaged approximately 500 employees 
and members of their families in a range of 
hands-on trainings and activities. Children had 
the opportunity to join in through a drawing 
competition and a competition where they 
built safety-themed “mascot” sculptures with 
recyclable materials.
In 2017, we launched the Road to Zero 
initiative across our manufacturing sites. The 
program utilizes teaming concepts to elevate 
employee involvement in project-based 
improvement activities. Since the program’s 
adoption, we have outperformed peer 
companies when it comes to annual recordable 
incident rates. (SASB FB-MP-320a.1)
Also in 2022, Phibro Bragança Paulista - 
Brazil achieved 5 years without work related 
accidents. This demonstrates the deep-seated 
appreciation of employees for the importance 
of preventive actions and the commitment 
to their own safety as well as that of their 
colleagues. (SASB FB-MP-320a.1)
 
 
Talent development is a strategic priority at 
Phibro. To ensure we have the right colleagues 
with the right skills in the right places to drive 
organizational results and ESG priorities, we 
nurture talent through multiple programs 
including:
LEADERSHIP DEVELOPMENT
New in 2022, Phibro selected 33 employees 
from North America for an intensive 
workshop-based training series that prepares 
them for increased levels of responsibility, 
supports the development of our culture and 
leadership behaviors and helps them chart 
their career paths.
MENTORING
An opportunity for professionals to be 
purposefully matched with an experienced 
senior level mentor, this global program 
brings people together across disciplines and 
geographies, fosters collaboration and promotes 
an inclusive working environment in which 
everyone’s contribution is recognized, valued 
and rewarded. The program was piloted in 
2021 and expanded to 36 participants in 2022, 
representing 18 matched pairs. 
GROWING GREAT LEADERS
33
ESG REPORT

4.0 
34
ESG REPORT
4.0
34
ESG REPORT
When interviewing candidates for a 
position, I always ask, “Why are you 
interested in this role?”
More often than not, candidates will 
answer that they have researched the 
company and found that the company’s 
values are in line with their own. These 
individuals recognize an important 
principle: values and core beliefs drive 
everything about an organization.
Five years ago, I was considering a 
job change and interviewed at Phibro 
Animal Health Corporation. I knew 
the moment I walked in the door and 
sat down with the leadership team 
that this was where I wanted to be. 
I had previously worked in human 
pharmaceuticals, starting as a research 
scientist and then moving into human 
resources after earning my graduate 
degree. After a few years in other 
industries, I was ready to return to 
the science and health space. More 
importantly, I wanted to work where I 
could best use my skills and experience.
WHY BELIEFS MATTER
Phibro’s strength is in its beliefs. The 
company has six values that are central 
to our identity and operation. When 
a company understands its beliefs, it 
helps to attract, retain and motivate 
people, and ensures the right people are 
in the right job.
The impact starts during the hiring 
process. Candidates today are looking 
for mission-driven organizations. 
It’s becoming even more important 
than salary or advancement as 
considerations in career decisions. They 
want to be part of something bigger 
than themselves and they want to know 
that the organization they are with 
has a clear vision. Phibro’s purpose of 
“optimizing animal health and nutrition 
for better lives and a more sustainable 
world,” whether that be domestically 
or in emerging markets, is a powerful 
mission. As we communicate that, it 
resonates with people.
Hiring is just the beginning. One of our 
beliefs is continuous investment in 
our people. From a human resources 
perspective, we want to ensure that 
we’re giving all our employees the 
resources they need to be successful. 
While it may sound cliché, I firmly 
believe that employees are our most 
important asset.
That belief is reflected in our leadership 
model that states a leader: 1) sees what 
needs to get done, 2) gets it done, and 
3) gets it done the right way. We’ve 
operationalized this model to ensure 
everyone understands that whether 
they’re an individual contributor or an 
executive, they have a role when it 
comes to leadership behaviors.
BELIEFS AND HR
More than 30 years of experience 
in human resources have shown 
me that HR is the essential link to 
operationalizing values Human resources 
functions best not when it is segregated 
into its own department but integrated 
into the company. Under Phibro’s HR 
operating model, HR professionals serve 
as business partners across the globe. 
HR professionals are aligned 
with functional leaders to partner 
with them every step of the way, 
understanding what their challenges 
are, and how to solve them together. 
Because HR has been able to provide 
a level of support throughout the 
organization, functional leaders often 
come to us and ask for our guidance on 
business decisions, and we are able to 
provide input that affirms Phibro’s 
core beliefs.
It was clear from the moment I joined 
Phibro that people and HR are a 
priority. One of our six beliefs is that 
people make an impact. I’ve had the 
opportunity since I have been here to 
put in place HR information systems, as 
well as performance management and 
talent development processes. These 
processes enable us to help our people 
succeed and ultimately fulfill our mission 
to keep animals healthy.
Values are the heart of an organization. 
Human resources is an essential 
component to enable team members 
to understand and carry out beliefs and 
values. When these are aligned, the 
organization excels.
Beliefs Connect Organizations 
with their Employees
Senior Vice President, Human Resources 
Phibro Animal Health Corporation

4.0 
35
ESG REPORT
4.0 
35
ESG REPORT
LENDING A HELPING HAND
Charitable activities across Phibro’s Israeli operations in 
2022 included the donation of dozens of gently used 
school backpacks before the start of the school year and 
an employee-led meet up to collect litter in a forest near 
the office.
A BRIDGE TO YOUTH 
EMPLOYABILITY
Fundación EMPUJAR (PUSH Foundation) is a non-profit 
organization that trains 18-24 year-olds in Argentina for 
entry into the labor market. Phibro provides scholarships 
and volunteers for the program, and two trainees joined 
the company in 2022 as full-time employees.
A GOOD NEIGHBOR
The employee-led Making a Difference Program provides 
assistance to local nursing homes, children’s homes, 
recovery houses, nonprofits and schools in Brazil. The 
annual activity calendar includes the Warm Campaign – 
which in 2022 resulted in donations of blankets and clothes 
benefiting nearly 250 people, donations of food and toys 
to families in need, as well as Entrepreneurship Workshops 
focused on crafts and cooking to promote sources of income 
for these families. The Program advances digital inclusion 
through the donation of Phibro computers and includes the 
sponsorship of a Literary Picnic, a community garden and 
sustainability lectures by Phibro employees.
We recognize that doing our part to 
contribute to the UN SDGs and local 
societal goals starts in the communities 
around the globe in which we operate. 
Following are just a few of the ways 
Phibro employees show up in their 
local communities, day in and day out. 
PHIBRO CARES
(GRI 203-2)

4.0 
36
ESG REPORT
PHIBRO CARES
4.0 
36
ESG REPORT
NEW LIFE FOR LAB 
MATERIALS
To integrate social and environmental concerns into our 
operations throughout Ireland, Phibro maintains a range 
of charitable initiatives. A highlight in 2022 was the 
donation of expired lab materials to Atlantic Technological 
University for students to use as part of their lab training. 
This donation served multiple purposes: reducing waste, 
keeping university costs down, and promoting the 
company’s linkages with the college.
A DIGITAL DONATION
In April 2022, company laptops that otherwise would 
have gone to the landfill were donated to a local 
nonprofit that helps young Malaysians access computers 
and engage in online learning. While this is a small 
gesture for Phibro, it is a big deal for each child who 
benefited from the program.
POR UN INVIERNO 
SIN FRÍO 1+1
To spread joy during Christmas season, Phibro Mexico 
partnered with “Mama AC” in Guadalajara, Jalisco – a 
nonprofit dedicated to supporting abandoned children 
– to distribute new clothes and toys to children in need. 
The program involves each donor persuading one more 
person to support the cause, thus “1+1.” In 2022, Phibro 
met our goal of sponsoring at least 50 children.
UNITED WAY ENGAGEMENT
Employees of Phibro’s Quincy, Ill. manufacturing facility 
joined more than 100 community volunteers, coordinated 
by United Way, to conduct hands-on service projects at the 
Quincy Public Schools junior high school. In addition, we 
raised money for the 2022 United Way Campaign inclusive 
of the company match, employee pledge contributions and 
employee-led fundraisers.

4.0 
37
ESG REPORT
With more than 1,800 people in 54 locations 
spanning 33 countries, Phibro is diverse by 
nature and takes extra steps to ensure unique 
traditions of the cultures that make up its 
vibrant global workforce are recognized. For 
example, it has been a tradition at Phibro 
China that the entire team and their family 
members gather before the Chinese New 
Year for activities and a group dinner to 
celebrate the achievements in the past year 
and welcome in the new one.
In June, Phibro locations in Brazil 
commemorate Festa Junina, an annual 
Catholic tradition in the country recognizing 
the harvest and the saints: Saint John, Saint 
Peter and Saint Anthony. Israeli locations 
gather to recognize Passover and Rosh 
Hashanah, the Jewish New Year.
These are just a few ways Phibro fosters an 
environment that celebrates each location’s 
individuality and makes sure that holidays 
important to its employees are important to 
the company too.
4.0 
37
ESG REPORT
CELEBRATING HOLIDAYS WITH 
OUR TEAMS AROUND THE GLOBE

4.0 
38
ESG REPORT
EMPLOYEE RECRUITMENT, DEVELOPMENT & RETENTION
CODE
TOPIC
DATA
Phibro metric
Employee Training:
Number of training hours completed per employee
2022 Avg Hours: 40
2021 Avg Hours: 40
Phibro metric
Employee Training:
Percipio Utilization
2022 Hours: 20,790, averaging 11 hours/employee
2021 Hours: 14,000, averging 8 hours/employee
Phibro metric
Diversity, Equity & Inclusion: 
Training Course 1 (Diversity, Inclusion, Sensitivity)
Training Course 2 (Unconscious Bias)
2022
Course 1 – 1,780 employees completed the course, representing a 94% participation rate
Course 2 – currently in progress
Phibro metric
Employee Development:
Educational Assistance Program
2022: 23 employees participating
2021: 21 employees participating
Phibro metric
Employee Development:
Mentorship Program
2022: 18 matched pairs
2021: 11 matched pairs
Phibro metric
Employee Development:
Leadership Program
2022 and 2021: 33 participants in North America
SASB HC-BP-330a.1
Employee Recruitment, Development & Retention:
Discussion of talent recruitment and retention efforts for 
scientists and research and development personnel
Phibro recruiting efforts for specialized roles in R&D utilizes search firms that focus on relevant 
scientific areas. In addition, we rely on professional and university networks of existing 
scientific personnel to identify candidates. When qualified candidates are identified, we provide 
relocation assistance, immigration assistance if necessary and/or other support.
Based on Phibro’s Materiality Assessment, we track and report our progress against the following Social Responsibility & Well-Being topics: 
Employee Recruitment, Development & Retention, Diversity, Equity & Inclusion, Employee Health & Safety, Labor Practices, Cybersecurity & Privacy 
and Customer Engagement & Welfare. Relevant SASB and GRI metrics, along with our current and prior years’ data, follow:
 
4.0 KEY PRIORITIES 
AND PROGRESS

4.0 
39
ESG REPORT
EMPLOYEE RECRUITMENT, DEVELOPMENT & RETENTION
CODE
TOPIC
DATA
SASB HC-BP-330a.2
Employee Recruitment, Development & Retention:
1) Voluntary and 
2) involuntary turnover rate for: 
a) executives/ senior managers, 
b) mid-level managers, 
c) professionals, and 
d) all others
	
2022 TURNOVER
Voluntary
Rate
Involuntary
Rate
Executive
1
1.9%
1
1.9%
Sr. Dir/Dir
9
7.5%
3
2.5%
Mid-Level Mgr
14
6.3%
7
3.1%
Supervisor/Prof
56
10.3%
26
4.8%
Entry/intermediate
136
14.3%
64
6.7%
Total 
216
11.4%
101
5.3%
Total # of employees
1,889
2021 TURNOVER
Voluntary
Rate
Involuntary
Rate
Executive
4
7.7%
2
3.8%
Sr. Dir/Dir
8
7.0%
3
2.6%
Mid-Level Mgr
21
10.3%
7
3.4%
Supervisor/Prof
49
9.3%
21
4.0%
Entry/intermediate
120
13.7%
61
7.0%
Total
202
11.4%
94
5.3%
Total # of employees
1,772
2020 TURNOVER
Voluntary
Rate
Involuntary
Rate
Executive
2
3.8%
2
3.8%
Sr. Dir/Dir
4
3.5%
8
7.0%
Mid-Level Mgr
16
7.5%
11
5.1%
Supervisor/Prof
49
9.7%
15
3.0%
Entry/intermediate
88
10.0%
50
5.7%
Total
159
9.0%
86
4.9%
Total # of employees
1,767

4.0 
40
ESG REPORT
EMPLOYEE RECRUITMENT, DEVELOPMENT & RETENTION
CODE
TOPIC
DATA
GRI 201-3
Economic Performance:
a) If the plan’s liabilities are met by the organization’s 
general resources, the estimated value of those 
liabilities. 
b) If a separate fund exists to pay the plan’s pension 
liabilities: i. the extent to which the scheme’s 
liabilities are estimated to be covered by the assets 
that have been set aside to meet them; ii. The basis 
on which that estimate has been arrived at; iii) when 
that estimate was made. 
c) If a fund set up to pay the plan’s pension liabilities is 
not fully covered, explain the strategy, if any, adopted 
by the employer to work towards full coverage, and 
the timescale, if any, by which the employer hopes to 
achieve full coverage. 
d) Percentage of salary contributed by employee or 
employer. 
e) Level of participation in retirement plans, such as 
participation in mandatory or voluntary schemes, 
regional, or country-based schemes, or those with 
financial impact.
a) As of June 30, 2022 and 2021 the pension plan for U.S. employees (which is no longer open 
to new participants) was 97% and 103% funded, respectively.
b) We have assets managed by a third-party advisor that invests in multiple funds, but it 
is generally one overall portfolio. The assets are measured at Fair Value. The liability is 
measured by our actuary with the difference being recorded on the balance sheet. There are 
several factors that go in the estimate of the liability (mortality rate, return on assets, discount 
rate). In order to pay plan participants, our advisor sells investments to generate the cash on 
an as-needed basis.
c) N/A
d) Employer contribution percentage is under the Company’s 401(k) plan, not the pension 
plan, and it is 100% of up to the first 6% of each employee’s contributions. Each year, at the 
Company’s discretion, they may elect to make an enhanced contribution to employee 401(k) 
accounts using a score calculated using a combination of age plus years of service.
e) For the Pension Plan, the Company makes the required contributions based on an 
actuarial analysis. 
The pension plan is currently frozen. No new employees have been eligible for the pension 
plan since January 1, 2014, and existing participants no longer receive credit for future 
service and compensation increases (as disclosed in our Annual Report). As of July 1, 2022, 
there are 606 participants. Under the 401(k) plan offered to U.S. employees, we have a 98% 
active participation rate as of December 31, 2022. Outside the U.S., Phibro offers retirement 
benefits at the local level, based on legal requirements and market practices.  
90% of 401(k) participants are achieving a 10% saving rate, which includes both employee 
and employer contributions, versus a same-size peer company average of 48% participation.
401(k) participants are achieving an annual average employee dollar contribution amount of 
$9,095 versus a same-size peer company average of $7,012.

4.0 
41
ESG REPORT
EMPLOYEE RECRUITMENT, DEVELOPMENT & RETENTION
CODE
TOPIC
DATA
GRI 202-2
Market Presence:
Proportion of senior management hired from the local 
community. 
a) Percentage of senior management at significant 
locations of operation that are hired from the local 
community. 
b) The definition used for ‘senior management’. 
c) The organization’s geographical definition of ‘local’. 
d) The definition used for ‘significant locations of 
operation’.
All (100%) from local community. Recruiting for all positions utilizes a mix of platforms to 
include posting vacancies on corporate careers webpage, recruiting platforms such as Indeed 
and LinkedIn as well as professional networking career sites. For executive level positions we 
utilize retained search firms to assist with candidate identification. Our recruitment geography 
for roles is focused on the local communities near our site locations. It is not our practice to 
relocate employees globally.
	
GRI 401-2
Employment:
a) Benefits which are standard for full-time employees 
of the organization but are not provided to temporary 
or part-time employees, by significant locations 
of operation. These include, as a minimum: i. life 
insurance; ii. health care; iii. disability and invalidity 
coverage; iv. parental leave; v. retirement provision; 
vi. stock ownership; vii. others. 
b) The definition used for ‘significant locations of 
operation’.
Significant area of operation: U.S.
Benefits are provided to employees who work at least 30 hours each week. These benefits 
include life insurance, health care (including dental and vision), short- and long-term disability 
insurance, accidental death and dismemberment insurance, travel assistance, retirement 
savings and pension plans (outside the U.S., where offered) and paid time off.

4.0 
42
ESG REPORT
2022
NONPRODUCTION 
GENDER GROUP 
BY LEVEL
PHIBRO VALUES DIVERSITY, 
EQUITY AND INCLUSION  
5+8+14+30+43
3% Mid-Level Manager
24% Professionals
16% Other colleagues
2+3+22+16+57
n = 1,130
*Note: Production line item shown here includes
 manufacturing, warehousing, and maintenance.
56+44
4
4
%
 
W
O
M
E
N
	
	
	
 
 
 
 
 
 
 
	
	
	
 
 
 
 
 
 
 
 
 
 
 
 
5
6
%
 
M
E
N
FEMALE
GENDER BY 
POSITION
1% Exec/Sr. Manager
MALE 
GENDER BY 
POSITION
8% Mid-Level Manager
5% Exec/Sr. Manager
29% Professionals
14% Other colleagues
Female
Male
Production
9%
91%
Nonproduction
44%
56%
Grand Total
30%
70%

4.0 
43
ESG REPORT
18% Latin America & Canada
2022 
NONPRODUCTION 
GENDER GROUP 
BY REGION
n = 1,130
57+43
4+11+18+22+45
12% Europe, Middle East & Africa
4% Asia Pacific 
MALE 
GENDER BY 
REGION
22% United States
3+15+11+16+55
PHIBRO VALUES DIVERSITY, 
EQUITY AND INCLUSION  
FEMALE
GENDER BY 
REGION
2% Asia Pacific
11% Latin America & Canada 
15% Europe, Middle East & Africa
16% United States
*Note: Production line item shown here includes
 manufacturing, warehousing, and maintenance.
Female
Male
Production
9%
91%
Nonproduction
44%
56%
Grand Total
30%
70%
4
4
%
 
W
O
M
E
N
	
	
	
 
 
 
 
 
 
 
	
	
	
 
 
 
 
 
 
 
 
 
 
 
 
5
6
%
 
M
E
N

4.0 
44
ESG REPORT
PHIBRO VALUES DIVERSITY, 
EQUITY AND INCLUSION 
2022
ETHNIC GROUP USA
REPRESENTATION
U.S. All Levels by Ethnicity
Count
% of Total
White
524
75%
Hispanic or Latino
95
13%
Black or African American
33
5%
Asian
28
4%
Two or More Races
14
2%
American Indian or Alaska Native
4
1%
Native Hawaiian or Other Pacific
2
0%
Total
700
100%
U.S. Management Level by Ethnicity
Count
% of Total
White
150
80%
Hispanic or Latino
16
9%
Black or African American
3
2%
Asian
14
7%
Two or More Races
3
2%
American Indian or Alaska Native
0
0%
Native Hawaiian or Other Pacific
1
0%
Total
187
100%

4.0 
45
ESG REPORT
EMPLOYEE HEALTH & SAFETY
CODE
TOPIC
DATA
SASB FB-MP-320a.1
Workforce Health & Safety:
1) Total recordable incident rate (TRIR) and
2) fatality rate
2022	
2021	
2020
1.51	
1.14	
0.57
0 	
0 	
   0
SASB FB-MP-320a.2
Workforce Health & Safety:
Description of efforts to assess, monitor and mitigate 
acute and chronic respiratory health conditions.
Phibro takes the respiratory health condition of its employees and air quality of all its facilities 
very seriously. To ensure the respiratory safety of our employees, we have developed and 
implemented two main policies (Industrial Hygiene and Respiratory Protection). These policies 
help drive a program that supports periodic evaluations, training, engineering controls, PPE 
and administrative support all in an effort to mitigate acute and chronic respiratory health 
conditions.
GRI 403-1
Occupational Health & Safety:
a) A statement of whether an occupational health and 
safety management system has been implemented, 
including whether: i. the system has been implemented 
because of legal requirements and, if so, a list of the 
requirements; ii. The system has been implemented 
based on recognized risk management and/or 
management system standards/guidelines and, if so, a 
list of the standards/guidelines. b) A description of the 
scope of workers, activities and workplaces covered 
by the occupational health and safety management 
system, and an explanation of whether and, if so, why 
any workers, activities, or workplaces are not covered
There are no specific legal EH&S System requirements for Phibro or requirements by any specific 
industry other than requirements by OSHA, EPA, DOT and other federal and local laws. However, 
Phibro has a management system in place that includes over 30 EH&S policies that integrate all 
our facilities despite their location internationally. Phibro Corporate policies serve as an umbrella 
for all our sites, but each site has site-specific adjustments based on their local laws. A list of 
EH&S Programs and Policies are maintained and updated periodically (they are also available 
on our intranet site). These documents drive our EH&S Management system and cover all our 
employees: factory, offices, sales, fleet, labs as well as employees working remotely.
Phibro Corporate Programs
• EH&S Management 
System
• Management of 
Safety Data Sheets & 
Formulations
• Internal and External 
Audits
• Employee Participation
• Hazardous 
Communication
• Waste Management
• Job Hazard Analysis
• Fleet Safety
• Sustainability
• Industrial Hygiene
• Hazardous Materials
Transportation
• Ergonomics
• Biosafety Program
• Armed Intruder Policy
Phibro Corporate Policies
• Incident Communication
• Forklift
• Ladder Safety
• Hot Work
• Lock Out and Tag Out
• Bloodborne Pathogens
• Emergency Response
• Laboratory Safety
• Contractor Safety
• Fire Extinguisher
• Fall Protection
• Machine Guarding
• Confined Space
• Compressed Gas 
Cylinders
• Automated External 
Defibrillators
• General Safe Work 
Practices
• Respiratory Protection
• Personal Protective 
Equipment
• Incident Reporting
• Hearing Conservation
• Electrical Safety 
Procedures
• Slips, Trips and Falls
• First Aid
• Safety Showers & Eye 
Wash
• Workers Compensation
• Cold Stress Prevention 
Program
• Heat Stress Prevention 
Program
• Pathogen Positive Test 
Result Response Plan
Phibro Corporate Forms
• Phibro Incident 
Communication Policy 
Checklist

4.0 
46
ESG REPORT
EMPLOYEE HEALTH & SAFETY
CODE
TOPIC
DATA
GRI 403-3
Occupational Health & Safety:
A description of the occupational health services’ 
functions that contribute to the identification and 
elimination of hazards and minimization of risks, and 
an explanation of how the organization ensures the 
quality of these services and facilitates workers’ access 
to them
We have a number of policies to ensure that employees have the health service function 
needed to support them in their daily work. We have policies that provide EH&S Training. 
Programs that provide participation and incentives. We have agreements with local 
occupational doctors and therapy centers to prevent small injuries from becoming bigger issues. 
Our site EH&S Managers along with the Global Director of EH&S meet monthly to discuss 
and evaluate the over EH&S program. We look at relevant data such as OSHA Incident Rate, 
workers’ compensation claims, fleet safety claims and types of injuries. Depending on our 
evaluation we adjust our program or target initiatives to improve the program. We have a clear 
EH&S Goal to maintain every year, and we work to meet that goal.
GRI 403-4
Workforce Health & Safety:
a) A description of the processes for worker 
participation and consultation in the development, 
implementation and evaluation of the occupational 
health and safety management system, and for 
providing access to and communicating relevant 
information on occupational health and safety to 
workers. b) Where formal joint management–worker 
health and safety committees exist, a description of 
their responsibilities, meeting frequency, decision-
making authority and whether and, if so, why any 
workers are not represented by these committees
Employee engagement, involvement and participation in occupational health and safety is a 
priority for Phibro. We understand that without employee buy-in for a good safety culture it 
would be impossible to run a successful EH&S program. Therefore, we have a specific policy 
that was implemented over a decade ago, where all facilities are asked to include employees 
in their EH&S programs by participation in EH&S Committees, First Aid Teams, regular safety 
programs and other community-type safety outreach programs like training with the local fire 
departments. There are incentives programs as well and suggestion boxes for safety program 
improvements.

4.0 
47
ESG REPORT
LABOR PRACTICES
CODE
TOPIC
DATA
SASB FB-FR-310a.1
Labor Practices:
1) Average hourly wage and 
2) percentage of in-store and distribution center 
employees earning minimum wage, by region
Hourly wage of production employees:
U.S.: 2022 - $21.78; 2021 - $21.47
Israel: 2022 – 71.85 ILS; 2021 – 62.43 ILS
Brazil: not meaningful; only apprentices paid hourly
Note: Part 2 does not apply to Phibro employees.
SASB FB-FR-310a.2
Labor Practices:
Percentage of active workforce covered under collective 
bargaining agreements
Argentina: 2022 – 28%; 2021 – 28%
Brazil: 2022 – 100%; 2021 – 100%
EU: 2022 – 11%; 2021 – 11%
Israel: 2022 – 63%; 2021 – 63%
U.S.: 2022 – 0%; 2021 – 0%
SASB FB-FR-310a.3
Labor Practices:
1) Number of work stoppages and 
2) total days idle
1) 2022 and 2021 – 0
2) 2022 and 2021 – 0
SASB FB-FR-310a.4
Labor Practices:
Total amount of monetary losses as a result of legal 
proceedings associated with: 
1) labor law violations and 
2) employment discrimination
1) 2022 and 2021 – None reported
2) 2022 and 2021 – None reported

4.0 
48
ESG REPORT
CYBER SECURITY & PRIVACY
CODE
TOPIC
DATA
SASB FB-FR-230a.2 
Data Security:
Description of approach to identifying and addressing 
data security risks
Phibro has documented policies as it relates to IT and Cybersecurity, developed in 
collaboration with HR and Legal. Data security and privacy are significant priorities, and tools 
are in place to ensure the safety and well-being of client, employee and company information. 
Encryption and zero-trust network protection technology inspect electronic transactions for 
corruption and/or cyberattacks.
Phibro employees are regularly trained and tested for cybersecurity awareness. Multi-factor 
authentication and active threat protection software further protect company devices and 
email from cyberattacks such as malware, phishing and ransomware. Quality compliance 
software allows Phibro to electronically sign, protect and store key documents, manage 
corporate policy and regulatory documents, standardize change control processes, track 
deviations and Corrective and Preventive Actions (CAPA) and ensure appropriate approval 
before changes are activated.
Phibro actively uses established processes for backup and recovery of all on-premises and 
cloud-based systems and data. In 2022, a global disaster and recovery program focused on 
our plants was tested and completed. Phibro strives to demonstrate an effective, risk-based 
approach to assure cybersecurity and protect confidential information
CUSTOMER ENGAGEMENT & WELFARE
CODE
TOPIC
DATA
SASB FB-FR-260a.1
Product Health & Nutrition:
Revenue from products labeled and/or marketed to 
promote health and nutrition attributes
2022             2021                2020
$894             $809                $738         Revenue in Millions
 92%              92%                 92%         % of Total Revenue      
SASB FB-FR-260a.2
Product Health & Nutrition:
Discussion of the process to identify and manage 
products and ingredients related to nutritional and 
health concerns among consumers
Our food animal products must be safe not only for the animals themselves but must also be 
safe for people who consume meat, milk, seafood and eggs that come from those animals.

5.0
49

5.0 
50
ESG REPORT
Phibro’s framework for corporate governance 
is intended to decrease business risk, 
maximize value and utilize the company’s 
resources in an efficient, sustainable manner, 
to the benefit of shareholders, employees 
and society at large.
Phibro is a “controlled company” under the 
Nasdaq stock market (“Nasdaq”) corporate 
governance standards. For details on 
this designation and other aspects of our 
governance, see our 2022 Proxy Statement, 
filed with the SEC.
Among its primary responsibilities, the Board 
of Directors (Board) oversees our strategic 
and business planning processes, monitors 
corporate performance and assesses the 
integrity and effectiveness of our internal 
controls, legal procedures, ethics and 
compliance programs. Beyond these core 
responsibilities, the Board is responsible for 
establishing and maintaining an effective 
leadership structure for the Company, 
as well as overseeing the executive 
management team.
BEST OF BOTH WORLDS: 
FAMILY-BASED VALUES AND 
DIVERSE PERSPECTIVES
We believe fresh perspectives and new 
ideas are critical to a forward-looking and 
strategic Board. Meanwhile, given the 
complex nature of our business, it is equally 
important to have the valuable experience 
and institutional knowledge that longer-
serving directors bring to the boardroom. In 
light of multi-generational leadership from 
the Bendheim family, Phibro takes pride in 
the continuity of our management and our 
track record in maintaining longstanding 
commitments.
Our directors bring diverse skills and 
experiences to the Board, including expertise 
in executive management, leadership, 
finance, financial reporting, manufacturing, 
technology, product commercialization, 
animal health and risk management.
 
5.0 FAIR AND TRANSPARENT 
GOVERNANCE
TAKING THE 3Rs TO HEART
At Phibro, we deliver innovation that we believe 
improves the health of animals, the livelihood 
of people who care for animals and the planet 
we inhabit together. Our animal welfare policy 
describes the responsibilities, guiding principles 
and philosophy associated with research 
conducted by Phibro. The guiding philosophy is 
our commitment to the 3Rs – refining, reducing 
and replacing animals in research where possible. 
Our goal is to maintain the highest moral and 
ethical standards for the care and treatment of 
animals to minimize discomfort and pain.
Case in point: at one of our U.S. research centers, 
we conduct nutritional studies with chickens. At 
the conclusion of these studies, they are offered 
to local individuals who wish to keep them as 
backyard chickens.
(SASB FB-FR-430a.3)

5.0 
51
ESG REPORT
We recognize the benefits of racial, gender, 
ethnic and experience-based diversity, 
and value the healthy debate that stems 
from different viewpoints. We aim to 
reflect our diverse customer and employee 
base; accordingly, our Board includes 
differing geographic, business and cultural 
backgrounds. 
While the Board of Directors does not 
have a formal diversity policy related to 
the evaluation of nominees to the Board, 
diversity is a factor considered when 
identifying prospective nominees. A new, 
independent director, Alejandro Bernal, was 
appointed in February of 2023, bringing the 
total of independent directors to six out of 
nine and further emphasizing Phibro’s
commitment to broaden our reach to 
companion animals. 
OUR SOLEMN OATH: ETHICS-
RELATED POLICIES
As part of a global value chain, Phibro is 
directly and indirectly exposed to ethical 
risks through our business operations. This 
includes good corporate governance, local 
and industry-specific business ethics norms, 
ethical R&D activities, as well as anti-
corruption and adherence to Phibro’s beliefs 
and respect for human rights.
Phibro typically includes statements 
in contracts with business partners 
and suppliers that parties are obliged 
to follow all applicable laws, rules and 
regulations. There have not been any cases 
of terminations or contracts not being 
renewed due to suspected business ethics 
breaches or corruption in the reporting 
period, nor has Phibro been involved in 
any legal proceedings regarding business 
ethics or corruption. Employees can report 
suspected cases of business ethics breaches 
or corruption through an anonymous 
whistleblowing channel. All employees have 
been introduced to the channel, both in 
meetings and in writing.
As outlined in our Anti-Bribery and 
Corruption Policy, Phibro has a zero-
tolerance approach to all forms of bribery 
and corruption (in line with the UN Global 
Compact Principle 10). Phibro and our 
employees will not offer or receive any bribe 
or facilitation payment or enter into corrupt 
practices of any kind. The policy covers 
bribes, gifts and hospitality, facilitation 
payments, political contributions and 
charitable contributions. Our Supplier and 
Vendor Code of Conduct establishes clear 
expectations for our suppliers and vendors 
with respect to ethics, business conduct, 
anti-bribery and corruption and other 
important compliance areas.
The management systems and process 
for assessing and mitigating bribery and 
corruption risks internally and in our supply 
chain are supported by specific actions 
including:
• Regular assessment of business activities 
and risks;
• Due diligence on suppliers and third-party 
distributors; and
• Reports to the Audit Committee on 
material issues with details of relevant 
follow-up actions.

5.0 
52
ESG REPORT
LEADERSHIP OVERSIGHT OF 
PHIBRO’S ESG JOURNEY
Our Chief Financial Officer, Damian Finio, is 
responsible for the advancement of our ESG 
program, including our assessment of key 
ESG risks and opportunities.
Relevant ESG topics, risks, issues and 
considerations – largely informed by related 
stakeholder feedback and the use of SASB 
and GRI frameworks – are overseen by our 
board liaison, Carol Wrenn, who has been a 
director since July 2010 and who also serves 
as a member of the Audit Committee and the 
Compensation Committee.
ADDRESSING RISK FACTORS 
THAT AFFECT OUR BUSINESS
Our corporate governance efforts are highly 
focused on effectively managing risk and 
preserving long-term, sustainable value 
for the benefit of our shareholders, our 
employees and the broader ecosystem in 
which we operate.
Phibro’s Annual Report for the year ending 
June 30, 2022, presents certain risks we 
face in the operation of our business. For 
a summary of such details, see our 2022 
Annual Report on Form 10-K. The Board,
either directly or through its committees,
routinely reviews Phibro’s business 
strategy and management’s assessment 
of related risks and discusses with 
management the appropriate level of 
risk depending on the market environment 
and other relevant factors.

5.0 
53
ESG REPORT
BUSINESS ETHICS
CODE
TOPIC
DATA
SASB HC-BP-510a.1
Business Ethics:
Total amount of monetary losses as a 
result of legal proceedings associated 
with corruption and bribery
2022: None reported
2021: None reported
SASB HC-BP-270a.2
Business Ethics:
Description of code of ethics governing 
promotion of off-label use of products
While Phibro does not have an internal code of ethics on off-label use, we do not promote or encourage any 
off-label use of our products. Some markets permit off-label use of some products through veterinary 
prescription. Phibro maintains a formal marketing materials review process involving both the regulatory 
department and in the United States, the Legal Department to ensure, amongst other regulatory and legal 
requirements, that promoted product uses are consistent with the approved uses of our products.
Phibro metric
Business Ethics:
Description of Business Ethics Policies
Code of Ethics: Our Code of Business Conduct and Ethics (“Code of Conduct”) applies to all our employees, 
including our executive officers. We also have a Code of Ethics for the Chief Executive Officer and Senior Financial 
Officers (“Code of Ethics”), which applies only to our executive officers and certain members of our management. 
Our Code of Conduct and Code of Ethics are designed to ensure that the highest ethical standards are properly 
communicated and adhered to in all realms of our business. Each year we administer companywide training on 
our Code of Conduct, which contains practical guidelines and examples of situations employees might encounter 
to help guide their decision- making processes. Our Code of Conduct encourages all our employees to speak 
up when they see conduct that is inconsistent with our high ethical standards and provides resources for 
up-the-chain reporting. There are several ways in which employees can raise concerns about suspected 
violations, misconduct or unsafe conditions, including our independent third-party operated EthicsPoint hotline, 
available 24/7, through which reports can be made confidentially and anonymously. In addition to the EthicsPoint 
hotline, employees are encouraged to address questions and concerns to, or to seek help and guidance from, their 
supervisor, or to report concerns directly to the Human Resources Department, the Legal Department and/or the 
Company’s Audit Committee.
Based on Phibro’s Materiality Assessment, we track and report our progress against the following Fair & Transparent Governance topics: Business 
Ethics, Selling Practices & Product Labeling and Product Design & Lifecycle Management. Relevant SASB and GRI metrics, along with our current 
data, and prior years’ follow:
 
5.0 KEY PRIORITIES AND PROGRESS

5.0 
54
ESG REPORT
BUSINESS ETHICS
CODE
TOPIC
DATA
Phibro metric
Business Ethics:
Description of Board of Directors 
1) Committee and
2) Independence
Board Committees: Our Board of Directors has two standing committees, an Audit Committee and a 
Compensation Committee. Each of the committees reports to the Board. In the future, our Board may establish 
other committees, as it deems appropriate, to assist it with its responsibilities. Our Audit Committee’s 
responsibilities include overseeing our relationship with our independent registered public accounting firm (our 
“external auditor”) (e.g., their independence from management; the scope and results of their audit; review and 
monitoring of our accounting principles, accounting policies, financial and accounting controls and compliance 
with legal and regulatory requirements); establishing procedures for the confidential anonymous submission 
of concerns regarding questionable accounting, internal controls or auditing matters; reviewing and approving 
related party transactions; and oversight of our risk management process.
Our Compensation Committee’s responsibilities include reviewing key employee compensation goals, policies, 
plans and programs; overseeing the compensation of our directors, chief executive officer and other executive 
officers; reviewing and approving employment agreements and other similar arrangements between us and 
our executive officers; and administering our stock plans and other incentive compensation plans, if any. Our 
Compensation Committee regularly reviews our executive compensation program to ensure that compensation 
is closely tied to aspects of our performance that our executive officers can impact and that are likely to have 
an impact on stockholder value. On an annual basis, our Compensation Committee evaluates the performance 
of our Chief Executive Officer and approves his compensation. Our Chief Executive Officer annually reviews the 
performance of our executive officers, including the named executive officers (other than himself/herself), with 
our Compensation Committee and makes recommendations to our Compensation Committee with regard to 
each executive officer’s compensation (other than himself/herself). Our Compensation Committee considers such 
recommendations when approving each executive officer’s compensation (other than the Chief Executive Officer). 
Our Compensation Committee annually evaluates the compensation of our directors in light of their duties and 
makes recommendations with regard to their compensation to our Board for approval.
Independence: Jack C. Bendheim, our Chairman, President and Chief Executive Officer, has sole authority to vote 
shares of our stock owned by BFI Co., LLC, an investment vehicle of the Bendheim family. Because BFI controls 
a majority of the combined voting power of our outstanding common stock, we are a controlled company under 
the Nasdaq corporate governance standards. As a controlled company, we are exempt from the requirement that 
a majority of our Board consist of “independent directors,” as defined under such rules. Nevertheless, our Board 
has reviewed the independence of its current members in accordance with the independence requirements of the 
applicable Nasdaq rules and has determined that the majority of our directors are “independent directors” under 
the relevant Nasdaq rules.

5.0 
55
ESG REPORT
SELLING PRACTICES & PRODUCT LABELING
CODE
TOPIC
DATA
SASB FB-FR-270a.1
Product Labeling & Marketing:
Number of incidents of non-compliance 
with industry or regulatory labeling and/
or marketing codes
2022: None reported
2021: None reported
All promotional materials and communications must be accurate, not misleading and compliant with all applicable 
legal and regulatory standards, including any applicable standards addressing off-label promotion, substantiation, 
scientific rigor and fair balance. Colleagues in sales, marketing, technical services and regulatory functions must 
comply with local or regional policies with respect to labeling, promotional programs, product samples and other 
related topics. Technical and regulatory review operates on a regional basis to review and approve marketing and 
promotional materials prior to their use.
SASB FB-FR-270a.2
Product Labeling & Marketing:
Total amount of monetary losses as a 
result of legal proceedings associated 
with marketing and/or labeling practices
2022: None reported
2021: None reported
PRODUCT DESIGN & LIFECYCLE MANAGEMENT
CODE
TOPIC
DATA
SASB HC-MS-410a.1
Product Design & Lifecycle 
Management:
Discussion of process to assess and 
manage environmental and human 
health considerations associated with 
chemicals in products, and meet demand 
for sustainable products
Our products meet FDA standards in the U.S. and other regulatory standards in each country for tissue residue 
and environmental impact.

6.0
56

2.0
57
ESG REPORT
Ingenuity and the application of science are humankind’s most powerful tools for realizing a better 
future. Phibro’s people are finding new solutions every day to keep animals healthy and more 
broadly contribute to societal goals.
We are proud of the step-changes we have made to elevate our ESG approach over the last 
two years and we will continue to evolve and strengthen our initiatives in the year ahead. In 
doing so, we will deliver greater value for our stakeholders, realize our long-term strategic 
goals and address societal challenges across the pillars of animal health, human health 
and planetary health.
 6.0 
6.0 NEXT STEPS ON 
OUR ESG JOURNEY
6.0
57
ESG REPORT

7.0
58

7.0 
59
ESG REPORT
GRI INDEX*
GRI 201: ECONOMIC PERFORMANCE 2016
Code
Disclosure(s)
Response
201-3
Defined benefit plan obligations and other retirement plans
P. 40
GRI 202: MARKET PRESENCE 2016
Code
Disclosure(s)
Response
202-2
Proportion of senior management hired from the local community
P. 41
GRI 203: INDIRECT ECONOMIC IMPACTS 2016
Code
Disclosure(s)
Response
203-2
Significant indirect economic impacts
PP. 35-36
GRI 306: WASTE 2020
Code
Disclosure(s)
Response
306-2
Management of significant waste-related impacts
PP. 22, 29
GRI 401: EMPLOYMENT 2016
Code
Disclosure(s)
Response
401-2
Benefits provided to full time employees that are not provided to temporary or part-time employees
P. 41
GRI 403: OCCUPATIONAL HEALTH AND SAFETY 2018
403-1
Occupations health and safety management system
P. 45
403-3
Occupational health services
P. 46
403-4
Worker participation, consultation, and communication on occupational health and safety
P. 46
7.0 APPENDIX
*This material references the title and publication year of the standard in the sub headers

7.0 
60
ESG REPORT
SASB INDEX
TOPIC
ACCOUNTING METRIC
CODE
RESPONSE
Business Ethics
Total amount of monetary losses as a result of legal proceedings associated with bribery or corruption
HC-BP-510a.1
P. 53
Description of code of ethics governing interactions with health care professionals
HC-BP-510a.2
Not applicable
Data Security
Description of approach to identifying and addressing data security risks
FB-FR-230a.2
P. 48
Drug Safety
List of products listed in the Food and Drug Administration’s (FDA) MedWatch Safety Alerts for Human 
Medical Products database
HC-BP-250a.1
Not applicable
Number of fatalities associated with products as reported in the FDA Adverse Event Reporting System
HC-BP-250a.2
Number of recalls issued, total units recalled
HC-BP-250a.3
Total amount of product accepted for take-back, reuse, or disposal
HC-BP-250a.4
Number of FDA enforcement actions taken in response to violations of current Good Manufacturing 
Practices (cGMP), by type
HC-BP-250a.5
Employee Recruitment, 
Development & Retention
Discussion of talent recruitment and retention efforts for scientists and research and development 
personnel
HC-BP-330a.1
P. 38
(1) Voluntary and (2) involuntary turnover rate for: (a) executives/senior managers, (b) mid-level managers, 
(c) professionals, and (d) all others
HC-BP-330a.2
P. 39
Energy Management
(1) Total energy consumed, (2) percentage grid electricity, (3) percentage renewable
FB-MP-130a.1
P. 27
Ethical Marketing
Total amount of monetary losses as a result of legal proceedings associated with false marketing claims
HC-BP-270a.1
Not applicable
Description of code of ethics governing promotion of off-label use of products
HC-BP-270a.2
P. 53

7.0 
61
ESG REPORT
SASB INDEX
TOPIC
ACCOUNTING METRIC
CODE
RESPONSE
Food Safety
Global Food Safety Initiative (GFSI) audit (1) non-conformance rate and (2) associated corrective action rate 
for (a) major and (b) minor non-conformances
FB-MP-250a.1
Not applicable
Percentage of supplier facilities certified to a Global Food Safety Initiative (GFSI) food safety certification 
program
FB-MP-250a.2
(1) number of recalls issued and (2) total weight of products recalled
FB-MP-250a.3
Discussion of markets that ban imports of the entity’s products
FB-MP-250a.4
Greenhouse Gas Emissions
Gross global Scope 1 emissions
FB-MP-110a.1
P. 26
Labor Practices
(1) Average hourly wage and (2) percentage of in-store and distribution center employees earning 
minimum wage, by region
FB-FR-310a.1
P. 47
Percentage of active workforce covered under collective bargaining agreements
FB-FR-310a.2
P. 47
(1) Number of work stoppages and (2) total days idle
FB-FR-310a.3
P. 47
Total amount of monetary losses as a result of legal proceedings associated with: (1) labor law violations 
and (2) employment discrimination
FB-FR-310a.4
P. 47
Management of 
Environmental & Social 
Impacts in the Supplly 
Chain
Revenue from products third-party certified to environmental or social sustainability sourcing standards
FB-FR-430a.1
Not applicable
Percentage of revenue from (1) eggs that originated from a cage-free environment and (2) pork produced 
without the use of gestation crates
FB-FR-430a.2
Not applicable
Discussion of strategy to management environmental and social risks within the supply chain, including 
animal welfare
FB-FR-430a.3
PP. 11, 12, 20, 32, 50
Product Health & Nutrition
Revenue from products labeled and/or marketed to promote health and nutrition attributes
FB-FR-260a.1
P. 48
Discussion of the process to identify and manage products and ingredients related to nutritional health 
concerns among consumers
FB-FR-260a.2
PP. 19, 48

7.0 
62
ESG REPORT
SASB INDEX
TOPIC
ACCOUNTING METRIC
CODE
RESPONSE
Product Labeling & 
Marketing
Number of incidents of non-compliance with industry or regulatory labeling and/or marketing codes
FB-FR-270a.1
P. 55
Total amount of monetary losses as a result of legal proceedings associated with marketing and/or labeling 
practices
FB-FR-270a.2
P. 55
Product Design & Lifecycle 
Management
Discussion of process to assess and manage environmental and human health considerations associated 
with chemicals in products, and meet demand for sustainable products
HC-MS-410a.1
P. 55
Product Safety
Number of recalls issued, total units recalled
HC-MS-250a.1
Not applicable
List of products listed in the FDA’s MedWatch Safety Alerts for Human Medical Products database
HC-MS-250a.2
Number of fatalities related to products as reported in the FDA Manufacturer and Use Facility Device 
Experience database
HC-MS-250a.3
Number of FDA enforcement actions taken in response to violations of current Good Manufacturing 
Practices (cGMP), by type
HC-MS-250a.4
Supply Chain Management
Percentage of (1) entity’s facilities and (2) Tier I suppliers’ facilities participating in third-party audit 
programs for manufacturing and product quality
HC-MS-430a.1
Not applicable
Description of efforts to maintain traceability within the distribution chain
HC-MS-430a.2
Description of the management of risks associated with the use of critical materials
HC-MS-430a.3
Water Management
(1) Total water withdrawn, (2) total water consumed, percentage of each in regions with High or Extremely 
High Baseline Water Stress
FB-MP-140a.1
P. 28
Description of water management risks and discussion of strategies and practices to mitigate those risks
FB-MP-140a.2
P. 24
Workforce Health & Safety
(1) Total recordable incident rate (TRIR) and 
(2) Fatality rate
FB-MP-320a.1
PP. 33, 45
Description of efforts to assess, monitor and mitigate acute and chronic respiratory health conditions
FB-MP-320a.2
P. 45

FORWARD-LOOKING STATEMENTS
This Report contains forward-looking statements that are 
subject to risks and uncertainties. All statements other 
than statements of historical or current fact included in 
this Report are forward-looking statements. Forward-
looking statements discuss our current expectations and 
projections relating to our financial condition, results of 
operations, plans, objectives, future performance and 
business. You can identify forward-looking statements 
by the fact that they do not relate strictly to historical or 
current facts. These statements may include words such as 
“aim,” “anticipate,” “believe,” “estimate,” “expect,” “forecast,” 
“outlook,” “potential,” “project,” “projection,” “plan,” “intend,” 
“seek,” “may,” “could,” “would,” “will,” “should,” “can,” “can 
have,” “likely,” the negatives thereof and other words and 
terms of similar meaning in connection with any discussion 
of the timing or nature of future operating or financial 
performance or other events. For example, all statements 
we make relating to our estimated and projected earnings, 
revenues, costs, expenditures, cash flows, growth rates 
and financial results, our plans and objectives for future 
operations, growth or initiatives, strategies, or the expected 
outcome or impact of pending or threatened litigation 
are forward-looking statements. All forward-looking 
statements are subject to risks and uncertainties that may 
cause actual results to differ materially from those that we 
expected. Examples of such risks and uncertainties include:
• The negative effects of a pandemic, epidemic, or outbreak 
of an infectious disease in humans, such as COVID 19, on 
our business, financial results, manufacturing facilities and 
supply chain, as well as our customers, protein processors 
and markets;
• Perceived adverse effects on human health linked to the 
consumption of food derived from animals that utilize 
our products could cause a decline in the sales of those 
products;
• Restrictions on the use of antibacterials in food-producing 
animals may become more prevalent;
• The potential FDA withdrawal of approval of our Mecadox 
(carbadox) product;
• A material portion of our sales and gross profits are 
generated by antibacterials and other related products;
• Competition in each of our markets from a number of 
large and small companies, some of which have greater 
financial, research and development (“R&D”), production 
and other resources than we have;
• Outbreaks of animal diseases could significantly reduce 
demand for our products;
• Our business may be negatively affected by weather 
conditions and the availability of natural resources;
• Climate change could have a material adverse impact on 
our operations and our customers’ businesses;
• Actions of regulatory bodies, including obtaining 
approvals related to the testing, manufacturing and 
marketing of certain of our products; 
• The continuing trend toward consolidation of certain 
customer groups as well as the emergence of large 
buying groups;
• Our ability to control costs and expenses;
• Any unforeseen material loss or casualty;
• Misuse or extra-label use of our products;
• Exposure relating to rising costs and reduced customer 
income;
• Heightened competition, including those from generics 
and those deriving from advances in veterinary medical 
practices and animal health technologies;
• Unanticipated safety or efficacy concerns;
• Our dependence on suppliers having current regulatory 
approvals;
• Our raw materials are subject to price fluctuations and 
their availability can be limited;
• Natural and man-made disasters, including but not limited 
to fire, snow and ice storms, flood, hail, hurricanes and 
earthquakes;
• Business interruption from political and social instability, 
including crime, civil disturbance, terrorist activities, 
outbreaks of disease and pandemics and armed conflicts, 
such as the current armed conflict between Russia and 
Ukraine;
• Terrorist attacks, particularly attacks on or within markets 
in which we operate;
• Risks related to changes in tax rates and exposure;
• Our ability to successfully implement our strategic 
initiatives;
• Our reliance on the continued operation of our 
manufacturing facilities and application of our intellectual 
property;
• Adverse U.S. and international economic market 
conditions, including currency fluctuations;
• Failure of our product approval, R&D, acquisition and 
licensing efforts to generate new products;
• The risks of product liability claims, legal proceedings and 
general litigation expenses;
• The impact of current and future laws and regulatory 
changes, including risks related to the protection of our 
customers’ privacy and risks related to environmental, 
health and safety laws and regulations;
• Modification of foreign trade policy may harm our food 
animal product customers;
• Our dependence on our Israeli and Brazilian operations;
• Impact of increased or decreased inventory levels at our 
direct customers or channel distributors;
• Our substantial level of indebtedness and related debt-
service obligations;
• Restrictions imposed by covenants in our debt 
agreements;
• The risk of work stoppages; and
• Other factors as described in “Risk Factors” in Item 1A of 
our most recent Annual Report on Form 10-K.
While we believe that our assumptions are reasonable, 
we caution that it is very difficult to predict the impact of 
known factors, and it is impossible for us to anticipate all 
factors that could affect our actual results. Important factors 
that could cause actual results to differ materially from our 
expectations, or cautionary statements, are disclosed under 
“Risk Factors” and “Management’s Discussion and Analysis 
of Financial Condition and Results of Operations” of our 
most recent Annual Report on Form 10-K and subsequent 
reports filed with the SEC. All forward-looking statements 
are expressly qualified in their entirety by these cautionary 
statements. You should evaluate all forward-looking 
statements made in this Report in the context of these risks 
and uncertainties.
We caution you that the important factors referenced above 
may not contain all of the factors that are important to 
you. In addition, we cannot assure you that we will realize 
the results or developments we expect or anticipate or, 
even if substantially realized, that they will result in the 
consequences we anticipate or affect us or our operations 
in the way we expect. The forward-looking statements 
included in this Report are made only as of the date hereof. 
We undertake no obligation to publicly update or revise any 
forward-looking statement as a result of new information, 
future events or otherwise, except as otherwise required 
by law. If we do update one or more forward-looking 
statements, no inference should be made that we will make 
additional updates with respect to those or other forward-
looking statements.

For updates on how we are advancing care for 
animals for the benefit of people and the planet, 
visit www.pahc.com/responsibility.
HUMAN RESOURCE INQUIRIES
LISA ESCUDERO
Phibro Animal Health Corporation
ESG Council Social Lead
Senior Vice President, Human Resources
humanresources@pahc.com
BY MAIL
PHIBRO ANIMAL 
HEALTH CORPORATION
Glenpointe Centre East, 3rd Floor
300 Frank W. Burr Boulevard, Suite 21
Teaneck, NJ 07666-6712 USA
GENERAL INQUIRIES
DAMIAN FINIO
Phibro Animal Health Corporation
ESG Council Chairman
Chief Financial Officer
investor.relations@pahc.com
MS033723GLB